08 - The Breast Gyan - Vahini

From

FOGSI, Food Drugs & Medicosurgical Equipment Committee August - 2025

Breast Health: Every Stage, Every Woman

Dr. Asha Jain

Editor & Chairperson, FOGSI FDMSE Committee

Message From Dr. Sunita Tandulwadkar

Dr. Sunita Tandulwadkar

President FOGSI-2025

It gives me great pleasure to present the August 2025 issue of our E-magazine dedicated to the theme “Breast”. The subject is of immense importance for every obstetrician and gynaecologist, as breast health spans across all stages of a woman’s life—from adolescence to menopause.

This issue covers a wide spectrum, starting from nutrition and physiological changes to advanced pharmacological and surgical interventions. The thoughtful articles on breast health in adolescents, pregnancy, lactation, and menopause remind us of the continuum of care that must be ensured. Equally significant are the chapters on breast imaging, biopsy devices, sterilisation protocols, and medicolegal aspects, which provide practical guidance to the busy clinician.

Of particular relevance are the discussions on emerging pharmacotherapies, mastalgia management, and innovations in surgical equipment. With breast cancer continuing to be one of the most pressing health concerns for women, these updates will help our members remain abreast of evolving therapies and safer practices.

I congratulate the FOGSI Food, Drugs and Medicosurgical Equipment Committee for curating such a comprehensive edition, and I sincerely thank all the contributing authors for their dedication and scholarship. This magazine is yet another step towards equipping our fraternity with evidence-based knowledge, thereby strengthening the care we provide to women across India.

Dr. Sunita Tandulwadkar
President, FOGSI

Message from Dr Abha Singh

Dr. Abha Singh
Vice President FOGSI-2025

Dear Fogsians , Seasons Greetings!

The August 2025 edition of our E-magazine on “Breast” highlights a subject that touches every woman’s health journey. The breast is an organ that is a symbol of life, nourishment and identity. At the same time it is also a centre of health challenges affecting millions of women globally, ranging from benign breast diseases to cancer .

Whether it is the developing adolescent, the pregnant or lactating mother, or the menopausal woman, breast health requires continuous attention, understanding, and compassionate management of the womens problem.
The chapters compiled in this issue reflect the diversity of challenges and opportunities in breast care. The articles on nutrition, hormonal influences, and drug therapies provide the scientific foundation for safe prescribing. At the same time, the chapters on prosthetics, reconstruction, imaging modalities, and medicolegal aspects address the practical realities we face in day-to-day practice.

What makes this issue truly valuable is the balance between preventive approaches, like infection control and health promotion, and advanced interventions, such as reconstructive surgery and emerging oncological pharmacotherapies. It ensures that the reader can find both clinical guidance and academic depth in one place.

As Vice President Incharge, I am proud to see the committee’s consistent efforts to bring forth high-quality, peer-informed articles for our members. I express my appreciation to the chairperson and all authors who have contributed to this e -magazine. I am confident that this edition will serve as a good reference for gynaecologists and obstetricians who wish to enhance their practice with evidence-based insights into breast health."
Let’s celebrate awareness, encourage regular check-ups with required management ans thus,embrace the message that Healthy breasts mean Healthier lives.

Happy Reading !

Dr Abha Singh
VP Fogsi

Message from Dr Suvarna Khadilkar

Dr. Suvarna Khadilkar
Secretary General FOGSI-2025

It is my privilege to introduce the August 2025 E-magazine with its theme "Breast", a subject that resonates deeply with the well-being of women. As clinicians, we frequently encounter patients with breast concerns, ranging from benign disorders and mastalgia to imaging dilemmas and cancer care. This compilation comes at the right time, offering both clarity and direction to practitioners.

The edition is rich in content, beginning with preventive and nutritional aspects, and moving systematically to diagnostic tools, medical and surgical devices, and therapeutic strategies. Articles on topical agents, drugs affecting lactation, and pharmacological management of breast disorders bring practical tips to the clinician's desk. At the same time, chapters on reconstruction, prosthetics, and innovations in surgical equipment address modern-day needs and aspirations of women seeking comprehensive breast care.

The section on medicolegal perspectives is especially welcome, as it sensitises us to safe practice and documentation—an area often overlooked despite its critical importance.
I warmly congratulate the Food, Drugs and Medicosurgical Equipment Committee for their dedicated efforts in curating this edition and thank all the authors for their scholarly contributions. I also express gratitude to our President and Vice President Incharge for their continuous encouragement and vision.

I am confident that this E-magazine will prove to be an enlightening resource for every gynaecologist and obstetrician, strengthening our mission to provide holistic, preventive, and evidence-based care to women across the country.

With best and warm wishes,

Dr. Suvarna Khadilkar
Secretary General, FOGSI

Dr. Asha Jain
Chairperson
FOGSI FDMSE Committee

FOREWORD

It gives me great pleasure to present the August 2025 edition of the FOGSI Food, Drugs and Medicosurgical Equipment Committee E-magazine on the theme "Breast." Breast health is integral to every stage of a woman's life and is frequently encountered in our practice as gynaecologists. This issue aims to provide a comprehensive, evidence-based resource that will guide us in prevention, diagnosis, and management of breast-related concerns.

Acknowledgements
I extend my sincere gratitude to our President, **Dr. Sunita Tandulwadkar**, for her visionary leadership, to our Vice President Incharge, **Dr. Abha Singh**, for her active support, and to our Hon. General Secretary, **Dr. Suvarna Khadilkar**, for her constant encouragement. Their guidance has enabled this edition to take shape with depth and clarity.

Highlights
The strength of this issue lies in its wide coverage. **From nutrition and adolescent breast health** to **pregnancy**, **lactation, and menopause**, preventive care is well addressed. Practical aspects such as **breast imaging (Dr. Sangeeta Sujayasri), biopsy devices (Dr. Archana Singh), infection control (Dr. Shikha Sachan), and mastalgia management (Dr. Jyothi G.S.)** provide ready clinical guidance.

Equally important are chapters on hormonal influences (**Dr. Prerna Saigal), pharmacotherapies in breast cancer (Dr. Asha Jain), and topical agents in breast disorders (Dr. Neetha George). Dr. Sugandha Goel** sensitises us to prosthetics and reconstruction, while **Dr. Raghweshwar Jyoti Mahajan** reminds us of the vital **medicolegal aspects**. Preventive, therapeutic, and legal dimensions are all thoughtfully included.

I wish to especially thank all our authors—**Dr. Deepti Gupta, Dr. Kiran Chhabra, Dr. Sandhya Rani Panigrahi, Dr. Sonal Gupta, Dr. Chandra Ponnusamy, Dr. Monica Umbardand, Dr. Prabdeep Kaur,** for their scholarly and timely contributions.

Editorial Note

This edition reflects our committee's philosophy—to prepare content that is practical, evidence-based, and relevant for everyday practice. The balance between preventive measures, advanced therapies, and medicolegal awareness makes this issue unique.
My gratitude also goes to **Mr. Bhupendra**, whose design work has given the magazine a professional finish.

Conclusion

I am confident that this issue will serve as a useful reference for every gynaecologist and obstetrician. It will help us provide women with holistic, safe, and compassionate breast care—ranging from the simplest complaint of mastalgia to the complex challenges of cancer and reconstruction.

Dr. Asha Jain
Editor, FOGSI FDMSE Committee E-magazine

"Know Your Numbers" is an ambitious health initiative.

- This project seeks to gather vital health data- Weight, Blood pressure, Blood Sugar Level with HbA1C, and Hemoglobin level -from women across India.
- By focusing on these key health indicators, the project aims to foster a proactive health management culture among women.
- The data collected will be instrumental in identifying prevalent health issues early and promoting interventions that can significantly reduce the incidence of che diseases.
- This initiative not only emphasizes the importance of regular health monitoring but also strives to empower women with the knowledge and tools needed to take charge of their health, ensuring they lead longer, healthier lives.
- Collect key health data: weight, blood pressure, blood sugar, HbA1C, and hemoglobin from women across India.
- Encourage proactive health management for early identification of prevalent health issues.
- Promote timely interventions to reduce chronic disease incidence.
- Empower women with knowledge and tools for better health and longevity.
- Gather vital health data: weight, blood pressure, blood sugar (HbA1C), and haemoglobin levels from women across India.
- Foster proactive health management among women.
- Identify prevalent health issues early and promote timely interventions.
- Reduce the incidence of chronic diseases through regular monitoring.
- Empower women with knowledge and tools for healthier, longer lives.

SURVEY FOR KNOW YOUR NUMBER (KYN) PROJECT

KNOW YOUR NUMBER

FOGSI FOOD DRUGS & MEDICOSURGICAL EQUIPMENT COMMITTEE

ADVISORS

Dr. Narendra Malhotra
Past President Fogsi

Dr P C Mahapatra
Past President Fogsi

Dr Rishma Pai
Past President Fogsi

Dr Jaydeep Tank
Imm. Past President

Dr Ashok Khurana
Patron Society of SFM

Dr, Rajendra Singh Pardeshi
Past VP Fogsi

Dr Vidya Thobbi
VP Elect Fogsi

Dr Ragini Agrawal
Past VP Fogsi

Dr Ritu Khanna
Past CP FDMSEC

COMMITTEE - MEMBERS

Dr Arati Kulkarni
Aurangabad MH

Dr Archana Singh
Hyderabad Telangana

Dr Chitra Pandey
Prayagraj UP

Dr Dolly Mehra
Ratlam MP

Dr Durgadas Asranna
Tumkur Karnataka

Dr E S Usha
Erode TN

Dr GinnyGupta
Ludhiana Punjab

Dr Himleena Gautam
Assam

Dr Ishan P Shah
Mehsana Gujrat

Dr Jyothi GS
Bangalore Karnataka

Dr Kiran Chhabra
Delhi

Dr M Chandra Ponnusami
Namakkal Tamil Nadu

Dr Neetha George
Thrissur Kerala

Dr Nidhi Bajaj
Katni MP

Dr Okram Sarda Devi
Imphal Manipur

Dr.Padmaja Veeramachaneni
Vijayawada

Dr Prabhdeep Kaur
Bhilai CG

Dr Prerna Saigal
Pathankot Punjab

Dr Priyanka Rai
Deoghar Jharkhand

Dr Ragweshwar Jyoti Mahajan
Shimla Himanchal Pradesh

Dr Renu Jain
Gwalior

Dr Rimpi Singla
Chandigarh

Dr Ruche Bhargava
Jalandhar Punjab

Dr Sandhyarani Panigrahi
Berhampur Odisha

Dr Sarita Kumari
Jamshedpur Jharkhand

Dr Shikha Sachan
Varanasi UP

Dr Sonal Gupta
Faridabad Hariyana

Dr Sreedevi Vellanki
Vijaywada AP

Dr Sugandha Goel
Jodhpur Rajasthan

Dr Sujaysri Sangita
Bhimavaram AP

Dr Urvashi Barman Singh
Prayagraj UP

Dr Vandana Gupta
Delhi

Dr Vishnu Priya
Bangalore Karnataka

INDEX

1 Nutrition and Breast Health: Evidence-Based Recommendations

Author :- Dr. Deepti Gupta
Associate Professor, Department of Obstetrics & Gynaecology, NSCB MCH Jabalpur
Consultant & Unit Head, Ankur Fertility Clinic and IVF Centre Jabalpur

BACKGROUND

Benign breast diseases constitute a heterogeneous group of disorders including developmental abnormality, epithelial and stromal proliferation, inflammatory lesions and neoplasm. Benign breast lesions deserve attention because of their high prevalence, their impact on women's life and due to cancerous potential of some histological types. Understanding the epidemiology and presentation of BBD is vital to reducing patient's anxiety, avoiding unwarranted interventions, and hence changing clinical management. Since women diagnosed with BBD comprise a large proportion of future breast cancer cases (~ 30%), it is important to identify factors associated with subsequent BC.

HOW NUTRITION CAN IMPACT BREAST HEALTH

The dietary changes that characterize the "nutrition transition" include both quantitative and qualitative changes in the diet. The adverse dietary changes include shifts in the structure of the diet towards a higher energy density diet with a greater role for fat and added sugars in foods, greater saturated fat intake (mostly from animal sources), reduced intakes of complex carbohydrates and dietary fibre, and reduced fruit and vegetable intakes. These dietary changes are compounded by lifestyle changes that reflect reduced physical activity at work and during leisure time.

Chronic diseases are largely preventable diseases. Although more basic research may be needed on some aspects of the mechanisms that link diet to health. Traditional, largely plant-based diets have been swiftly replaced by high-fat, energy-dense diets with a substantial content of animal-based foods. There has been a remarkable increase in the intake of dietary fats over the past three decades. There are multiple pathways by which altered diet and physical activity pattern may affect non-malignant & malignant breast disorders like

- Altered estrogen levels.
- Altered estrogen metabolism.
- Oxidative stress
- Obesity

Foundational Dietary Patterns: The Macro Approach

Following are few recommendations to optimise breast health by optimising nutrition.
Indian population has shown only steady level of consumption of only 120--140 g fruits/ vegetables per capita per day, in various surveys.

Figure 1.1. Food pyramid for balanced diet for 2000 Kcal

1. Plant-Forward Eating Patterns

The EPIC Study (n=335,054 women) demonstrated that those consuming predominantly whole plant foods had:

- - 14% lower overall breast cancer risk
- - 20-34% reduced risk of postmenopausal ER- tumors
- - Significant reduction in recurrence among survivors

Key mechanisms: Fiber binds excess estrogen for elimination, antioxidants neutralize DNA-damaging free radicals, and anti-inflammatory compounds inhibit tumor microenvironment formation.

2. Mediterranean Diet: Gold Standard Protection

Analysis of 26 studies confirms adherence reduces risk by 15-40% through:

- Extra virgin olive oil: Phenolic compounds (oleocanthal) induce cancer cell apoptosis.
- Fatty fish: Omega-3s (EPA/DHA) suppress COX-2 inflammation pathways.
- Colourful produce: Carotenoids (lycopene, lutein) protect ductal epithelial cells.

Critical note: Traditional Mediterranean diets include minimal alcohol—a key modification for breast health.

3. The Western Diet Hazard

Regular consumption of processed foods correlates with:

- 23% increased breast cancer risk (NIH-AARP study)
- Higher breast density on mammograms
- Elevated IGF-1 growth factors that stimulate cell proliferation.

Primary offenders: Sugar-sweetened beverages, refined grains, processed meats, and industrial seed oils high in omega-6 fatty acids.

Table: Comparing Dietary Patterns for Breast Health

Pattern	Key Components	Associated Risk Impact	Primary Protective Mechanisms
Healthful Plant-Based	Fruits, vegetables, whole grains, legumes, nuts, healthy plant oils	11% overall risk reduction	Weight management, phytochemicals, fibre
Mediterranean	Vegetables, fruits, fish, olive oil, whole grains, legumes	40% reduction in ER-postmenopausal cancer	Anti-inflammatory fats, antioxidants
Western	Red/processed meats, saturated fats, sugary beverages, refined grains	Increased risk	Promotes inflammation, insulin resistance, obesity

II. Functional Foods: Targeted Nutritional Défense

1. Cruciferous Vegetables: Cellular Detoxifiers

- Broccoli sprouts: Sulforaphane upregulates phase II detox enzymes (glutathione)
- Kale/Cabbage: Indole-3-carbinol promotes beneficial 2-hydroxyestrone metabolism.
- Dose: 1/2 cup daily reduces risk 15% (Nurses' Health Study II)

2. Berries & Stone Fruits: Angiogenesis Inhibitors

- Ellagic acid (raspberries, pomegranates): Blocks VEGF tumor blood vessel formation
- Anthocyanins (blueberries, cherries): Reduce oxidative stress in breast tissue.
- Clinical finding: Women consuming >3 servings/week had 25% lower ER- cancer risk.

3. Flaxseeds & Sesame: Phytoestrogen Modulators

- Lignans bind estrogen receptors weakly, blocking stronger endogenous estrogens.
- Enterolactone (gut metabolite) inhibits aromatase enzyme activity.
- Impact: 2 tbsp ground flaxseed daily reduced Ki-67 tumor proliferation markers by 34%

4. Soy Foods: Dispelling Myths

- After decades of controversy, meta-analyses confirm:
- Pre-menopausal women: 1-2 servings/day reduce risk 28%.
- Post-menopausal: Genistein inhibits tyrosine kinase signalling pathways.
- Survivors: 25% lower recurrence with moderate soy intake
- Key distinction: Whole soy foods (tofu, tempeh) ≠ isolated soy supplements

5. Mushrooms & Sea Vegetables

- Reishi/Lion's Mane: Beta-glucans enhance natural killer cell activity.
- Kelp/Wakame: Fucoidan compounds inhibit cancer cell migration.
- Epidemiology: Japanese women consuming seaweed daily have 50% lower breast cancer rates

III. Weight Management: The Estrogen Connection

The Adipose Tissue-Endocrine Axis

- Postmenopausal women with obesity face 30-60% higher risk because:
- Adipocytes convert androgens → estradiol via aromatase enzymes.
- Leptin/adiponectin dysregulation promotes inflammation.
- Hyperinsulinemia increases bioavailable IGF-1

Strategic Weight Management

- Pre-menopause: Focus on preventing weight gain (>10 lbs increase raises risk 18%)
- Perimenopause: Prioritize muscle mass preservation (resistance training + 25g protein/meal)
- Post menopause: Targeted loss—women losing >10% body weight reduce risk 32%.
- Metabolically Healthy Obesity Paradox
- Critical insight: Normal-weight women with metabolic dysfunction (insulin resistance, inflammation) have higher risk than obese women with healthy biomarkers—highlighting diet quality overweight alone.

IV. Hazard Mitigation: Substances Requiring Caution

1. Alcohol: Dose-Dependent Risk

- 1 drink/day: 7-10% risk increase
- 3+ drinks/day: 40-50% higher risk
- Mechanisms: Acetaldehyde DNA damage, folate depletion, elevated estradiol (especially luteal phase)

2. High-Temperature Cooking Compounds

- Heterocyclic amines (charred meats): Activate CYP1A2 carcinogen pathways.
- Acrylamide (fried starches): Induces oxidative stress.
- Solution: Marinate meats (rosemary/thyme reduce HCAs 90%), steam/sauté below 300°F

3. Endocrine Disruptors in Food Systems

- Pesticides (organophosphates): Mimic estrogen in MCF-7 cells
- Plasticizers (BPA/phthalates): Alter mammary gland development.
- Mitigation: Choose organic for produce, avoid canned foods, use glass storage

V. Life Stage Nutrition Strategies

Adolescence/Young Adulthood

- Crucial development window: Diets rich in carotenoids optimize breast tissue maturation.
- Fiber intake: >25g/day delays menarche, reducing lifetime estrogen exposure.

Reproductive Years

- Folate adequacy (600mcg DFE): Critical during rapid cell division cycles
- Iodine optimization: Deficiencies correlate with fibrocystic changes.

Perimenopause to post menopause.

- Phytoestrogen transition: Replace declining hormones with lignans/isoflavones.
- Vitamin D enhancement: Serum levels >40ng/ml associated with 50% lower risk.

Survivorship & Prevention

- Post-diagnosis nutrition: WHEL Study showed 67% reduced mortality with 5+ veg servings.
- Fasting-mimicking diets: Emerging evidence for chemotherapy protection

VI. Implementation Framework: Science to Plate



1. Plate Architecture for Prevention

- 50% non-starchy vegetables (cruciferous + alliums)
- 25% Plant protein (tofu/beans) or fatty fish
- 25% Resistant starch (legumes/whole grains)
- Add 1-2 tbsp seeds + herbs/spices.

2. Cultural Adaptations

- Asian: Increase seaweed, shiitake, daikon radish.
- Latin: Use nopales, beans, chia seeds.
- Mediterranean: Emphasize wild greens, sardines, EVOO.

3. Nutrient Synergy Spotlight

- Vitamin D + K2: Regulate calcium deposition away from breast tissue.
- Curcumin + Piperine: 2000x greater anti-inflammatory bioactivity
- Sulforaphane + Selenium: Boost glutathione peroxidase activity

4. Supplementation Considerations

- When diet falls short:
- Vitamin D3: 2000-5000 IU to achieve 40-60 ng/ml.
- Omega-3s: 1-2g EPA/DHA with tocopherols
- Probiotics: Lactobacillus strains modulate estrogen enterohepatic recycling

VII. Beyond Nutrition: Synergistic Protocols

1. Chrono-nutrition

- Time-restricted eating (12-hour window): Reduces nocturnal insulin spikes.
- Folate timing: Morning intake optimizes DHFR enzyme activity.

2. Exercise as Adjuvant Therapy

- 150 mins/week moderate activity: Lowers circulating estrogens 20%.
- Resistance training: Increases SHBG binding capacity.

3. Environmental Toxicology Mitigation

Air purification: Reduces PAH inhalation.

Night detox: Support phase III toxin clearance with magnesium/glycine

VIII. Implementation Strategies: From Science to Sustainable Practice

Translating nutritional science into daily eating patterns requires practical approaches:



- Practical Plate Composition: Aim to fill half your plate with colorful non-starchy vegetables and fruits, one-quarter with plant proteins (beans, lentils, tofu) or lean fish, and one-quarter with whole grains. This simple framework naturally incorporates protective foods while limiting those associated with increased risk.

- **Cultural and Personal Adaptation:** dietary recommendations should be adapted to reflect specific cultural traditions and local contexts" . Traditional diets from various cultures can be modified to enhance protective components—adding more vegetables to stews, incorporating indigenous whole grains, or using healthy traditional fats like olive oil or avocado.

- **Healthcare Provider Engagement:** Given the significant awareness gap—only 19% of women recall discussing nutrition's role in breast cancer prevention with providers—women should proactively initiate these conversations . Request specific guidance on dietary patterns rather than isolated superfoods or supplements.

- **Policy-Level Changes:** strategies like price reductions on healthier foods, taxes on sugar-sweetened beverages, and improved accessibility to physical activity spaces to create environments that support cancer-preventive lifestyles, especially among disadvantaged populations . Community initiatives like the Physicians Committee's "Let's Beat Breast Cancer" rallies also raise awareness about prevention strategies .

Conclusion: Empowering Dietary Agency

Emerging research confirms that nutrition may influence up to 70% of modifiable breast cancer risk factors. Unlike genetic predispositions, dietary patterns represent actionable leverage points:

1. Prioritize diversity in plant foods (aim for 30+ species weekly)
2. Optimize protein sources (legumes > fish > poultry > limited red meat)
3. Manage body composition through insulin-sensitizing foods
4. Mitigate toxins through organic choices and preparation methods
5. Synergize timing with circadian biology

While no single food guarantees immunity, the cumulative effect of daily choices creates a powerful biochemical environment hostile to malignancy. As research evolves toward precision nutrition—exploring nutrigenomics, the estrobolome, and individualized biomarkers—women now possess unprecedented tools to nourish breast health proactively across every life stage.

Suggested Reading

·WHO TRS 916. Diet, Nutrition & Prevention of Chronic Diseases
·ICMR NIN Dietary Guidelines for Indians.

2 Breast Health in Adolescents and Young Women:

Author :- Dr. Kiran Chhabra
Gynaecologist, MBBS, DGO,
Delhi

Introduction

Breast health is an important but often overlooked aspect of adolescent and young women's overall well-being. While breast cancer is rare in this age group, understanding normal development, recognizing warning signs, and adopting healthy practices early in life lay the foundation for lifelong breast health.

Equipping young women with knowledge also reduces anxiety and builds confidence around bodily changes during puberty and beyond. Basic knowledge of breast disease is as important as any other problem of uterus and ovary. Gynaecologists can make significant contribution in diagnosing occult breast disease.

Breast Development

Breast is hormone responsive tissue, which undergoes changes with every phase of women`s life. Breast development begins at puberty under influence of oestrogen.

Breast development is one of the earliest signs of puberty in girls and usually begins between ages 8 and 13. It follows a predictable pattern and may not always develop symmetrically — one breast may grow faster or appear larger than the other, which is usually normal.

Common changes during this phase include:

- Tenderness or soreness
- Appearance of firm lumps (related to hormonal changes)
- Sensitivity to touch
- Asymmetry in size or shape

These are generally normal and resolve with time.

Abnormalities or anomalies of breast can result in poor self-esteem and make herself conscious.

Common Breast Concerns in Young Women

While most breast changes in adolescents are benign (non-cancerous), it's important to differentiate between normal variations and issues that may need medical attention.

1) Developmental Abnormalities

a)Absence of nipple

b)Absence of breast tissue

c)Accessory breast tissue

2**) Abnormalities of size and asymmetry**

a)Small breasts or hypomastia rule out pubertal development, hypothyroidism, ovarian failure and androgen excess.

b)Bilateral small breasts with normal sexual development should be considered normal and reassured.
c)Breast Hypertrophy is uncommon Cause abnormal response to gonadal hormones, may cause backache and abnormal comments from peers.
d)Breast atrophy due to weight loss or chronic disease
e)Tuberous Breast. base of breast small and nipple and areola over developed cause not known.

3) Breast Pain
Related to hormonal Changes
Can occur with exercise can occur premenstrual, with oral contraceptive use, and in fibrocystic changes
Reassurance &Lifestyle modifications like wearing sports bra help

4) Breast Abscess
More prone to Mastitis (entry of pathogen to ductal system)
Causes- trauma, due to sexual activity, plucking of hair, nipple piercing,
Mammary duct ectasia.

5) Breast Mass
a. Fibroadenomas
These are the most common benign breast lumps in young women 30% to 50% They are smooth, rubbery, and move easily under the skin. They usually do not require removal unless they grow or cause discomfort.

b. Cysts (fibrocystic changes)
Etiology unknown but thought to result from imbalance between estrogen & progesterone.
Fluid-filled sacs that may fluctuate with the menstrual cycle. They can be tender but are usually harmless.

When to Seek Medical Advice

Young women should be encouraged to report the following to a healthcare provider:
• A new lump that persists or grows
• Nipple discharge (especially bloody or spontaneous)
• Skin changes such as dimpling, redness, or thickening
• Persistent pain in one area
• Changes in nipple position or shape

Promoting Breast Self-Awareness
Formal breast self-examinations (BSE) are no longer routinely recommended for adolescents, but breast self-awareness — knowing what's normal for your own body — is encouraged.
Teach young women to:
• Be familiar with how their breasts look and feel at different times of the month
• Gently observe and palpate their breasts monthly after the period ends
• Report unusual changes promptly, without panic

Healthy Lifestyle for Breast Health

Building healthy habits in adolescence supports lifelong breast health. Key recommendations include:
• Maintaining a healthy weight
• Limiting processed and high-fat foods
• Exercising regularly
• Avoiding smoking and excessive alcohol
• Wearing well-fitted, supportive bras, especially during sports

Mental Health and Body Image

Breast development can cause emotional and psychological stress in adolescents. Body image issues, teasing, or confusion about what is "normal" can affect self-esteem. Supportive conversations, accurate education, and open channels of communication with parents, teachers, or health providers are essential.

Breast conditions in AYA are usually benign, but awareness is essential Breast cancer in young women is less common but aggressive &is diagnosed late.
Young age Ca is associated with Genetic predisposition (Brica Mutations)

ASCO guidelines
1.Risk Awareness & Family history
History of Breast, Ovarian, Pancreatic & Prostatic Cancer
2. Genetic Counselling & Testing in age < 45.
3.Breast Self-Awareness not Examination
Educate about normal breast & when to report
4.Clinical Breast examination in high-risk individuals or if symptoms present
5.Imaging guidelines
Usg first line
Mammography not in < 30 except high risk
MRI in BRCA carriers from 25 years annually
6. Fertility Preservation discuss before treatment.
7. Psychosocial Support about body image, sexuality, fertility, mental health, depression & anxiety

Conclusion
Breast health education should start early — not to cause fear, but to empower. When young women understand their bodies, they are more likely to take charge of their health, recognize warning signs early, and seek appropriate care when needed. Encouraging a proactive, positive approach to breast health is an investment in their future well

Title: Nature's First Prescription

Author: Dr. Tuba Tahseen
Designation: 3rd year Junior Resident, AIIMS Raipur

In the hush of birth's first cry,
A reflex stirs, both low and high-
The rooting search, the open lips,
The latch that starts with gentle sips.

From breast to baby, a golden stream,
Colostrum flows- a newborn's dream.
Immunologic liquid gold,
With antibodies strong and bold.

IgA guards the infant's gut,
Seals each cell and closes shut
The doors where germs might find their way;
A shield to keep disease at bay.

Each feed adjusts, the milk transforms,
In rhythm with the baby's norms.
Foremilk cool, then hindmilk thick
Designed by nature, tailored quick.

It's more than food-it's medicine,
With hormones, fats, and leptin in.
It builds the brain, supports the heart,
And gives the lungs a healthy start.

Oxytocin in mother's blood
Lets milk down in a flowing flood.
But more than that, it bonds and ties
With love reflected in both eyes.

Prolactin surges through the night,
Ensuring that supply is right.
Each suckle signals: “Make some more”
A perfect system at its core.

Less risk of SIDS, less asthma too,
Less allergies and stomach flu.
It nurtures gut, defends the brain,
And guards the child through sun and rain.

For mother too, the gains run deep-
Less cancer, calmer postpartum sleep.
It tones the womb, reduces bleed,
And answers all her body's need.

So here’s to breast, both science and soul,
A living tissue with a goal
To heal, to feed, to gently start
The lifelong beat of a mother’s heart.

03 Breast changes during pregnancy and Lactation

Author- Dr.M.Chandra Ponnusamy,
MBBS,DGO,FICOG,DRM
Clinical Director, Chandra Nursing Home &
Fertility Centre,Namakkal,637001,Tamilnadu

During pregnancy , the breast undergoes both anatomic and physiologic changes to prepare for lactation. During the first trimester, the ductal system expands and branches out into the adiposetissue in response to the increase of estrogen. Elevated levels of estrogen also cause a decrease in adipose tissue and ductal proliferation and elongation. Estrogen also stimulates the pituitary gland which leads to elevated levels of prolactin. By the twentieth week of gestation, mammary glands are sufficiently developed to produce components of milk due to prolactin stimulation. Milk production is inhibited by high estrogen and progesterone levels and colostrum is produced during this time. In the third trimester and then rapidly after birth, these levels decrease, allowing for milk production and eventual let-down to allow for breastfeeding.

Breasts undergo significant changes as they prepare for lactation. These changes are primarily driven by hormonal fluctuations and include increased size, tenderness, darkening of the nipples and areolas, and the appearance of Montgomery's glands. Some women may also experience leaking of colostrum, the first milk, later in pregnancy.

These are the changes that occur in pregnancy.

Early Pregnancy changes: (First Trimester):

- Increased Size and Tenderness.
- Breast tenderness is often one of the earliest symptoms of pregnancy.:
- Breasts may become sore, heavy, or tingly as early as 1 to 2 weeks,after conception.
- Breasts may become larger and feel tender or sore due to hormonal changes, particularly increased progesterone levels.

Breast discomfort often subsides after a few weeks, although it may return later in pregnancy.

Nipple Sensitivity

- Rapid growth can cause the breasts to feel itchy as the skin stretches. The breasts may also continue to increase in size after birth during nursing.
- Some women experience heightened sensitivity or tingling in the nipples.

Darkening of Nipples and Areolas:

The areolas, the area around the nipples, may darken in color due to increased pigmentation.

Visible Veins:

- Increased blood flow to the breasts can make veins more prominent on the skin's surface

Later Pregnancy (Second and Third Trimesters):

Further Enlargement:

- Breasts continue to grow, and women may need to switch to larger, more supportive bras.

Colostrum Production:

- Colostrum, a thick, yellowish fluid, may begin to leak from the nipples, particularly in the later stages of pregnancy.

Montgomery's Glands:

- Small bumps may appear on the areolas. These are Montgomery's glands, which are oil-producing glands that help keep the nipples lubricated.



Stretch Marks:

- As the breasts grow, stretch marks may develop on the skin.

- Many breast changes that occur in the first and second trimesters will continue throughout the final months of pregnancy. The breasts can become even larger and heavier, the nipples may continue to darken, and the colostrum might leak more regularly.



Postpartum:

- **Milk Production:**
- After delivery, prolactin levels rise, initiating milk production and breastfeeding.

Involution:

If breastfeeding is discontinued, milk production will eventually cease, and the breasts will gradually return to their pre-pregnancy size .

There are international guidelines for breast care and breastfeeding.

NICE GUIDELINES

- The National Institute for Health and Care Excellence (NICE) published a guideline on postnatal care in 2021, which includes recommendations on breastfeeding. This guideline, NG194, covers the routine postnatal care for women and their babies in the first 8 weeks after birth, including baby feeding.

Key aspects of the NICE guideline related to breastfeeding include:

1.Acknowledging parental concerns:

The guideline emphasizes the importance of acknowledging parents' emotional, social, financial, and environmental concerns about feeding options and respecting their choices.

2.Supporting breastfeeding: It provides detailed guidance on supporting women to breastfeed, assessing breastfeeding and also covers formula feeding.

WHO recommendations:

- The guideline aligns with WHO recommendations for breastfeeding, including initiating breastfeeding within the first hour of birth and exclusive breastfeeding for the first six months.

Postnatal contacts:

- The guideline recommends at least three additional postnatal contacts for all mothers and newborns, in addition to the initial contact within 24 hours of birth. These contacts should be scheduled on day 3 (48-72 hours), between days 7-14 after birth, and at six weeks.

Emotional attachment:

- The guideline also covers the antenatal period regarding emotional attachment and baby feeding.

Addressing breastfeeding challenges: The guideline acknowledges that infant feeding often becomes a central issue in postnatal consultations, sometimes with specific aspects of feeding or its emotional impacts.

In essence NICE guideline on postnatal care (NG194) provides a framework for healthcare professionals to support breastfeeding mothers, address their concerns, and ensure optimal infant feeding practices in the first eight weeks after birth.

The Academy of Breastfeeding Medicine (ABM) is a global organization of physicians dedicated to the promotion, protection, and support of breastfeeding and human lactation.
It aims to bridge the gap between clinical practice and scientific knowledge by developing evidence-based protocols for managing common medical issues related to breastfeeding.

Goals of ABM are:-

Promote, protect, and support breastfeeding and human lactation

Develop clinical protocols:

Disseminate knowledge:

A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient.

PROTOCOLS

ABM publishes protocols to facilitate best practices in breastfeeding medicine. These protocols serve as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to an individual patient's needs. Breastfeeding complications can affect both the mother and the infant. For mothers, common issues include sore nipples, engorgement, blocked ducts, mastitis, and low milk supply.

ABM Clinical Protocol #4 provides evidence-based guidance for healthcare professionals managing mastitis in breastfeeding women, emphasizing the importance of a comprehensive approach that includes both medical and supportive care.

The protocol provides guidance on prevention, diagnosis, and treatment of mastitis, a common breastfeeding complication. It emphasizes the importance of supportive measures like rest, fluids, and appropriate medication, including analgesics and potentially antibiotics.

The protocol also highlights the need for further research into the role of probiotics and massage in managing mastitis.

References

- Waldenström U, Aarts C. Duration of breastfeeding and breastfeeding problems in relation to length of postpartum stay: A longitudinal cohort study of a national Swedish sample. Acta Paediatr 2004;93:669–676 - PubMed

- Foxman B, D'Arcy H, Gillespie B, et al. . Lactation mastitis: Occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol 2002;155:103–114 - PubMed

- Amir LH, Forster DA, Lumley J, et al. . A descriptive study of mastitis in Australian breastfeeding women: Incidence and determinants. BMC Public Health 2007;7:62. - PMC - PubMed

- Appendix A Task Force Ratings Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force, 2nd edition. www.ncbi.nlm.nih.gov/books/NBK15430 (accessed May7, 2014)

- Lawrence RA. The puerperium, breastfeeding, and breast milk. Curr Opin Obstet Gynecol 1990;2:23–30 - PubMed

----------xxxxx----------

4 Breast Health in Premenopausal and Menopausal Women

Author - Dr. Sonal Gupta
MBBS, MD
Faridabad Hariyana

Introduction

Breast health is a vital component of women's health and wellbeing, and given that women are often subject to a variety of complexities, it requires attention at different points throughout her life. The transition from pre-menopause to menopause can have major hormonal, metabolic and physical effects that react directly with breast tissue. These effects can impact not only benign conditions (such as mastalgia, cysts, and fibrocystic changes), but also influence the risks of malignant transformation. In particular, breast cancer is the most prevalent reported cancer among women globally, and remains a significant public health issue (Sung et al., 2021).

The importance of breast health for both premenopausal and menopausal women is critical for gynecologists who are often the initial contact women have with health, and for general readers who want to better understand how breast health changes with age. This article discusses physiological changes, risk factors, recommended screening, prevention, and current clinical practice, while considering the most up-to-date global and Indian author's guidelines.

1. Breast Physiology Across Life Stages

Premenopausal Breast Changes

Breast tissue is very responsive to changing ovarian hormones in the premenopausal state. All units of breast tissue undergo ductal proliferation when stimulated by estrogen, and lobular and alveolar differentiation if stimulated by progesterone (Anderson et al., 2014). Women in their reproductive years of experience cyclic mastalgia, premenstrual swelling, and tenderness, all of which are likely due to stimulation by reproductive hormones. During their reproductive years, women also often develop fibrocystic changes and benign breast disease, and studies show that as many as 50–60% of women experience benign breast disease during their reproductive years (Dixon & Mansel, 1994).

Menopausal Breast Changes

In menopause, the ovaries stop producing estrogen and progesterone, resulting in the involution of glandular tissue and its replacement by adipose tissue (Santen et al., 2020). This transition translates to softer breasts, less density, and fewer benign cyclical complaints. However, post-menopausal women face new dilemmas:

- Reduction in breast density may improve mammography sensitivity, but it does not reduce cancer risk.
- Hormone replacement therapy (HRT), which includes estrogenic agents that can include progestins, has been linked to elevated breast cancer risk (Chlebowski et al., 2020).

- Obesity and metabolic syndrome becomes important contributors to risk postmenopausal, friend of the hormonal decline.

2. Breast Cancer Risk Across Premenopausal and Menopausal Women

The risk of breast cancer is affected by many hormonal, genetic, environmental, and lifestyle factors. Age is the strongest risk factor for breast cancer, but different factors are taken into account in premenopausal versus menopausal subjects, and so on.

Risk in Premenopausal Women

Breast cancer in premenopausal women is rare, but it is often more aggressive. Evidence suggests that younger women with breast cancer tend to have tumors that are triple-negative and/or HER2-positive, which has been associated with poor prognosis (Azim et al., 2012). Importantly, some key risk factors contributing to development include:

- Genetic predisposition: BRCA1 and BRCA2 mutations carry a substantially higher risk compared to women with negative mutation status (King et al., 2003)
- Reproductive history: Early menarche, nulliparity and older age (≥30) at first birth carry increased risk (Collaborative Group on Hormonal Factors in Breast Cancer, 2012)
- Hormonal exposure: Especially in certain populations, use of high dose oral contraceptives has been associated with low to moderate increase in risk of breast cancer.

Risk in Menopausal Women

For women after menopause, cumulative lifetime exposure to estrogen, obesity and inactivity rule the day. After ovarian failure, adipose tissue is the primary source of estrogen, and this can lead to tumor development (Howell et al, 2014). Important risk factors include:

- Late menopause (age over 55).
- Hormone replacement therapy (HRT), particularly long-term use.
- Obesity and metabolic syndrome in relation to estrogen-positive breast cancers (Neuhouser et al., 2015).

3**. Benign Breast Disorders**

Benign breast diseases are prevalent, but their prevalence differs between premenopausal females and those who are postmenopausal.

- Premenopausal females: The benign breast diseases most prevalent are fibroadenomas, fibrocystic disease and mastalgia. These conditions are benign; however, they still can cause anxiety and can result in undesirable biopsies when no evaluation is performed.
- Postmenopausal females: Cysts generally regress, but palpating any lumps causes greater concern of the diagnosis being malignant. Gynecologists play a critical role in differentiating benign from malignant pathology through imaging and referral where appropriate.

4. Screening and Early Detection

Breast cancer prognosis is directly associated with early detection. Screening guidelines differ widely between countries; however, there is a general consensus concerning age, level of risk, and access to resources.

Screening in Premenopausal Women

Routine population-based mammography screening is generally not recommended for women under 40 years of age because the incidence is low, and younger women usually have denser breast tissue, which reduces mammography sensitivity (WHO, 2021). Instead, the focus is on the following:

- Breast self-awareness: Promoting an understanding of normal breast anatomy.
- Clinical breast examination (CBE): Particularly in low- and middle-income countries (LMICs) where mammography may not be available to all women; and
- Targeted imaging: Ultrasound or MRI for women at high risk, especially those with BRCA mutation-related breast cancer risk.

Screening in Menopausal Women

Mammography is most helpful for postmenopausal women. Guidelines state that:

- Age 40–49: screening is based on individualized risk
- Age 50–69: every 2 years (U.S. Preventive Services Task Force, 2016)
- Age 70 or older: screening should be considered based on life expectations for an individual, comorbidities, and screening history.

In India, the FOGSI Position Statement (2020) asserts that opportunistic screening should consist of Clinical Breast Exam (CBE) due to limited infrastructure; however, mammograms are encouraged for women over 50 years in urban areas and settings with many additional resources.

5. Prevention and Lifestyle Modification

Breast disease prevention requires individual and public health considerations. Evidence shows that modifiable risk factors are important independent determinants of breast cancer incidence, especially in postmenopausal women.

Some of the recommended preventive behaviors are:

- Maintaining or achieving a healthy body weight: Obesity appears to double the risk of postmenopausal breast cancer (Chan et al., 2014).
- Adequate physical activity: At least 150 minutes of moderate physical activity weekly lowers risk (McTiernan et al., 2019).
- Limiting alcohol: Even moderate alcohol consumption increases risk.
- A healthy diet: High fruit, vegetable, and whole grain diets reduce inflammation and metabolic risk.
- Avoidance of unneeded HRT: When HRT is indicated use the lowest effective dose for the shortest duration.

6.Psychosocial Aspects of Breast Health

Breast health problems have important results mentally and socially as well as biologically. When diagnosed with breast health issues, premenopausal women often grapple with anxieties about potential effects on fertility, alterations to their bodies, and sexuality or desire. Additionally, menopausal women may have compounded concerns about aging, fears of losing their femininity, and societal stigma surrounding breast cancer. Addressing psychosocial health is critically important. Studies have shown that patients who accessed multidisciplinary care combined with support, including gynecologists, oncologists, psychologists, and support programs, had improved treatment compliance and quality of life (Bender et al., 2014).

7. Advances in Diagnosis and Management

Contemporary breast health care incorporates imaging, genomics, and precision medicine.

- Imaging: Digital breast tomosynthesis is more sensitive than conventional mammography in dense breasts (McDonald et al., 2016).
- Genetic testing: The ability to offer the vast majority of women BRCA testing and multi-gene panel testing permits us to identify which women may be at the most risk.
- Targeted therapies: The advent of CDK4/6 inhibitors, PARP inhibitors, and evolving immunotherapy have created a paradigm shift in breast cancer treatment, particularly in challenging premenopausal aggressive disease (Turner et al., 2020).
- Minimally invasive surgery: By using sentinel lymph node biopsy and developing oncoplastic surgery, we can deliver a safe and effective surgical option that preserves function and appearance and addresses the psychosocial aspects of mastectomy rather than address it later.

Conclusion

Breast health in pre-menopausal and menopausal women reflects a continuum influenced by hormonal, lifestyle, and genetic factors. Benign breast disorders are prevalent in younger women, whereas the risk of malignancy increases as women age, particularly after menopause. Early detection, preventive tactics, and lifestyle modifications are the methods that affects outcomes the most. For gynecologists, being aware of internal modality with changing guidelines is of paramount importance to weigh the recommendation to SCREEN with the actual risk to the TARGET PATIENT.

Equally, appropriate and timely communication with patients that includes the physical and psychosocial aspects of breast health improvement is a key component to providing quality care. As genomics and precision oncology develop, health strategies will be more individualized. Ultimately, protecting breast health throughout women's lives will require integrated, multidisciplinary, patient-centered approaches.

References (Harvard Style)

- Anderson, T.J., Fergusson, D.J. and Forrest, A.P.M. (2014) Breast development and its disorders. Edinburgh: Churchill Livingstone.
- Azim, H.A., Partridge, A.H. and Gelber, S. (2012) 'Biology of breast cancer in young women', Breast Cancer Research, 14(4), pp. 212–220.

- Bender, C.M., Merriman, J.D. and Gentry, A.L. (2014) 'Psychological aspects of breast cancer', Journal of Clinical Oncology, 32(36), pp. 4070–4076.
- Chan, D.S., Vieira, A.R., Aune, D. et al. (2014) 'Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis', Breast Cancer Research and Treatment, 146(2), pp. 209–235.
- Chlebowski, R.T., Anderson, G.L., Aragaki, A.K. et al. (2020) 'Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women', JAMA, 324(4), pp. 369–380.
- Collaborative Group on Hormonal Factors in Breast Cancer (2012) 'Menarche, menopause, and breast cancer risk', The Lancet Oncology, 13(11), pp. 1141–1151.
- Dixon, J.M. and Mansel, R.E. (1994) 'Symptoms, diagnosis and treatment of benign breast disease', British Journal of Surgery, 81(5), pp. 716–719.
- FOGSI (2020) Position Statement on Breast Cancer Awareness and Screening. Federation of Obstetric and Gynaecological Societies of India.
- Howell, A., Anderson, A.S., Clarke, R.B. et al. (2014) 'Risk determination and prevention of breast cancer', Breast Cancer Research, 16(5), pp. 446–455.
- King, M.C., Marks, J.H. and Mandell, J.B. (2003) 'Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2', Science, 302(5645), pp. 643–646.
- McDonald, E.S., Oustimov, A., Weinstein, S.P. et al. (2016) 'Effectiveness of digital breast tomosynthesis compared with digital mammography', Radiology, 281(3), pp. 689–695.
- McTiernan, A., Friedenreich, C.M. and Katzmarzyk, P.T. (2019) 'Physical activity and cancer prevention', CA: A Cancer Journal for Clinicians, 69(2), pp. 88–112.
- Neuhouser, M.L., Aragaki, A.K., Prentice, R.L. et al. (2015) 'Overweight, obesity, and postmenopausal invasive breast cancer risk', JAMA Oncology, 1(5), pp. 611–621.
- Santen, R.J., Heitjan, D.F., Gompel, A. et al. (2020) 'Postmenopausal hormone therapy: an Endocrine Society scientific statement', Journal of Clinical Endocrinology & Metabolism, 105(12), pp. 4237–4265.
- Smith, R.A., Cokkinides, V. and Brawley, O.W. (2004) 'Cancer screening in the United States, 2004: A review', CA: A Cancer Journal for Clinicians, 54(1), pp. 41–52.
- Sung, H., Ferlay, J., Siegel, R.L. et al. (2021) 'Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide', CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249.
- Turner, N.C., Slamon, D.J., Ro, J. et al. (2020) 'Overall survival with palbociclib and fulvestrant in advanced breast cancer', New England Journal of Medicine, 379(20), pp. 1926–1936.
- US Preventive Services Task Force (2016) 'Screening for breast cancer: Recommendations and rationale', Annals of Internal Medicine, 164(4), pp. 279–296.
- WHO (2021) Breast cancer: prevention and control. World Health Organization.

----------XXXXX----------

05

Breast Health in Post Menopausal Women

Author- Dr. Sandhya Rani Panigrahy
FICOG MICOG FICMCH FAIOG FCGP CIPMS
Berhampur Odisha

Co-Author- Dr. Partha Sarathi Tripathy JR, MKCG Medical College Berhampur Odisha

Menopause is a natural stage in a woman's life that brings significant changes to the body including the breasts. During menopause breast changes occur due to shifting hormone levels, particularly the decline in estrogen. After menopause women may often experience several changes in breasts due to the decrease in your estrogen levels. Menopause brings about significant shifts in breast tissue due to fluctuating hormone levels. Explore the changes during this phase and care for the breast, screening is the main focus of this stage.

Declining estrogen — Reduction in breast density

Menopause triggers notable changes in breast tissue, primarily driven by declining estrogen levels. These changes include reduced breast density, increased tenderness, and potential sagging. While these transitions are normal, understanding them is crucial for maintaining breast health.

This article explores —

1. Physiological changes
2. Practical advice for breast care during menopause
3. Importance of regular screenings for overall well-being

Why do our breasts change during menopause?

As women transition through perimenopause, Menopause and postmenopause fluctuating and eventually declining estrogen levels have a noticeable impact on breast tissue. Estrogen is responsible for maintaining the density, shape, and elasticity of breasts. When these hormone levels drop breasts undergo several changes.

Physiological Changes:

1.**Reduced size and fullness** — As estrogen levels drop the glandular tissue in breasts shrinks which can lead to a decrease in breast size and fullness.

2.**Less firmness** — Breasts may lose volume and become less dense.Contributing to sagging. Research shows that about 80% of postmenopausal women experience reduced breast density making them feel less firm. The connective tissue in breasts becomes less elastic that can result in sagging and loss of firmness.

3.**Increased tenderness** — Fluctuations in estrogen during perimenopause can cause occasional swelling and soreness, affecting up to 65% of women during this stage.

4.Changes in texture —
Breast tissue becomes more fatty and less glandular making breasts softer, less denser and more prone to developing benign cysts. A study published in the journal "Menopause" found that postmenopausal women have approximately 35% more fat in their breast tissue compared to premenopausal women.

5.Nipple change — Nipples may become smaller and less pronounced. It may also notice that nipples become less sensitive.

6.Changes in skin — The skin on breasts can become thinner and may be more prone to wrinkles and dryness due to reduced collagen production and changes in skin elasticity.

7.Breast pain or discomfort — It may also experience tenderness or pain in breasts during the transition to Menopause but the pain or discomfort usually fades after menopause.

Concerned About Breast Pain After Menopause?
One common concern among postmenopausal women is breast pain after menopause. While breast pain is often associated with the menstrual cycle, it can still occur after menopause for various reasons, including:

Non-Cyclical Breast Pain: This type of pain is not linked to hormonal fluctuations and may be caused by factors such as inflammation, cysts or musculoskeletal issue. Residual Hormonal Effects: Although estrogen levels decline, fluctuations may still cause tenderness or discomfort
Breast Tissue Changes: The transformation of breast tissue composition can lead to increased sensitivity and pain. Any pain in Breast during menopause should not be overlook and ignore. It's advisable to consult health care professionals to rule out any pathology associate with it.

8.Lumpiness — While many benign breast lumps (such as cysts or fibroadenomas) often reduce in size or disappear after menopause, new lumps or changes should always be evaluated by medical provider.

9.Changes in breast density — Breast density can decrease after menopause which can be seen on mammograms. Less dense breasts contain more fatty tissue and less glandular tissue. Breast changes through the different stages of menopause

Perimenopause:-
Hormone fluctuations lead to tenderness and swelling in the breasts, similar to PMS symptoms. Fibrocystic changes (lumpy, fluid-filled cysts) may occur which typically disappear postmenopause. Up to 50% of women may experience these changes

Postmenopause:-
Breasts become less glandular and more fatty reducing firmness. A study in the European Journal of Cancer found that this change in breast composition occurs in approximately 75% of postmenopausal women.

Mammograms become easier to read due to reduced density but vigilance is still key for detecting any abnormal growths. The American Cancer Society recommends annual mammograms for women over 50, given that breast cancer risk increases significantly with age.

How to care for changing breasts

Choose the right support: Well-fitted bras that offer proper support can help with discomfort and sagging. Studies have shown that wearing a well-fitted bra can reduce breast pain by up to 85%.

Adopt healthy habits: Regular physical activity, weight management and a balanced diet rich in healthy fats and antioxidants can support breast health. Omega-3 fatty acids in particular have been linked to improved skin elasticity.

A study in the British Journal of Nutrition found that women who consumed higher levels of omega-3 fatty acids had better skin elasticity and fewer wrinkles.

Self-exams and screenings: Monthly self-breast exams and regular mammograms are essential.

According to The Journal of Women's Health, early detection improves breast cancer survival rates by up to 98% when caught early.

Moisturize and care for the skin: Since aging skin loses elasticity using moisturizers or oils with ingredients like Vitamin E can maintain skin health and texture.

A study in the Journal of Cosmetic : Dermatology found that topical application of vitamin E improved skin elasticity by 14% over a 4-week period.

When to seek medical advice- It's important to be aware of potential warning signs: - - - -

- New lumps or areas of thickening
- Unexplained nipple discharge or changes such as inversion or scaling
- Persistent pain not linked to your menstrual cycle
- Skin changes such as dimpling or redness

Early detection can make a significant difference as breast cancer detected early has a 99% five-year survival rate according to the American Cancer Society. Risk of breast cancer increases with age, especially after menopause. Around 8 out of 10 breast cancer cases happen in women over 50.

So maintaining breast health is important including regular mammograms. For screening self examination monthly and mammography every year. There are also women with increased breast density and recommend supplemental screening for those women.

Density in the breast tends to decrease a little bit with menopause because of loss of estrogen. Those women with rapid decline of density of Breast low risk of Breast cancer in comparison to slow decline of density of Breast. The shape, size and appearance of breasts change because of hormonal changes that take place in the body as women get older.

A loss of oestrogen can make the skin slack and dry and the breasts may look and feel less firm and full. Women may also notice that breasts droop more and there is a larger space between them than when women are younger. Some women find that their breasts get significantly smaller after menopause.

It is noticed for the breast to get bigger if they put on weight which is a common effect of menopause. The area of tissue around the nipple, known as the areola, tends to become smaller as age and most women find that they don't experience tenderness in their breasts as they used to usually in the run-up to

their periods. Some age-related breast changes are normal and ongoing breast care is vital.
"It's important to remember menopause to continue with breast cancer screening Pre menopausal. It's recommended to start regular breast cancer screening at age 40.

Reduce risks of breast cancer, optimize breast health Some risk factors for breast cancer like age, reproductive history and genetics (such as family history or BRCA gene changes)can't be changed. However, making certain lifestyle changes may help lower the risks.

How to reduce risks of breast cancer:

- Maintain a healthy weight
- Get regular exercise
- Limit alcohol consumption

Taking precautions for breast cancer after menopause involves a combination of lifestyle choices, regular screenings, and awareness of risk factors. Here are some of the key strategies that you may try:

Regular Screenings
Mammograms — Follow your medical provider's recommendations for mammography, typically every 1-2 years for women over 50.
Clinical Breast Exams — Have regular breast exams performed by the medical provider.

Self Awareness
Check the breasts for any changes, such as lumps, changes in size or shape, and skin or nipple changes.

Report Changes — Notify the medical provider immediately if notice any unusual changes.

Healthy Diet
Balanced Nutrition — Eat a diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats.
Limit Alcohol — Reduce your alcohol intake, as alcohol consumption is linked to an increased risk of breast cancer.

Maintain a Healthy Weight
Weight Management — Postmenopausal women who are overweight or obese have a higher risk of developing breast cancer. So, aim for a healthy weight through diet and exercise.

Regular Exercise

Physical Activity — Engage in regular physical activity, such as brisk walking, swimming, or cycling, for at least 150 minutes of moderate aerobic activity or 75 minutes of vigorous activity per week.

Avoid Smoking

Tobacco — Do not smoke, and avoid exposure to secondhand smoke, as smoking is linked to an increased risk of several cancers, including breast cancer.

Limit Hormone Reacrment Therapy (HRT)

HRT Use — If the woman need hormone replacement therapy for menopausal symptoms use the lowest effective dose for the shortest duration possible and discuss the risks and benefits with medical provider.

Risk Factors Awareness

Family History — Be aware of family history of breast cancer and discuss it with medical provider as this may affect the screening schedule and preventive measures.

Genetic Testing — Consider genetic counseling and testing if have a strong family history of breast cancer or known genetic mutations (e.g., BRCA1 or BRCA2).

Healthy Lifestyle

Stress Management — Practice stress-reducing activities such as yoga, meditation or deep breathing exercises.

Sleep — Ensure to get adequate sleep as poor sleep patterns can affect overall health.

Medication for High Risk women

Preventive Medications — For women at high risk of breast cancer, certain medications (such as selective estrogen receptor modulators) may be recommended to reduce risk. Discuss this option with the healthcare provider. Taking these precautions can help reduce the risk of breast cancer and ensure early detection, which is crucial for effective treatment and better outcomes. Always consult with healthcare provider for personalized advice and recommendations.

Breast lumps and cancer screening

The risk of developing breast cancer increases with age and it's always beneficial to be wary of potential signs and symptoms. The main changes to look out for include

- Abnormal lumps
- Swelling in the breast tissue
- Swelling around the armpits
- Discharge from the nipples
- Wrinkling of the skin around the nipples

Screening is provided on the NHS for women aged between 50 and 70 years old. Any of the symptoms listed above consult as early as possible consult Health professionals rather than waiting or screening test. In most cases, breast lumps are harmless cysts but it's always better to exclude the cancer on the side of caution.

Comprehensive Breast Care

As we all understand the concerns that come with breast changes during menopause. There should be dedicated breast specialist who provides comprehensive care tailored to women experiencing breast-related symptoms during menopause. With expertise in evaluating and managing breast health during menopause each patient receives the appropriate guidance, screenings and treatment options to maintain optimal health.

Supporting Breast Health Through Menopause

Menopause and breast changes go hand in hand bringing shifts in size, shape, and sensitivity. While many of these changes are a natural part of aging understanding what is normal and when to seek medical advice is essential.

Supporting women through every stage of menopause with expert guidance and compassionate care. Prioritising breast health means staying informed, scheduling regular screenings and making lifestyle choices that support long term well-being. It's concerned about Breast Health during Menopause. It's advised to all women not to hesitate to reach out for professional advise and support.

References –

1.Andrew lee Breast Clinic UK Feb 2025 update of Menopause and Breast Health

2.R.N., IBCLC, AHN-BC, CHT — Written by Natalie Silver — June 26, 2023

3.United Nations, Department of Economic and Social Affairs. (2021) World Prospects of Menopause 2021

4.United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Ageing and Menopause 2019

06

Breast Imaging Modalities: A Guide To Equipment And Usage

Author- Dr. Sangeeta Sujayasri
Sec Bhimavaram Obs & Gyn Society

Introduction:

Breast imaging stands at the forefront of early detection, diagnosis, and management of breast diseases—most notably, breast cancer, the most common malignancy among women worldwide. The evolution of imaging modalities over recent decades has revolutionized breast care, offering clinicians an increasingly sophisticated arsenal of tools to characterize lesions, guide interventions, and monitor therapeutic response with precision and confidence.

This chapter, "Breast Imaging Modalities: A Guide to Equipment and Usage," provides a comprehensive overview of the core and emerging technologies shaping modern breast imaging practice. From the foundational techniques of mammography and ultrasound to advanced modalities such as digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), contrast-enhanced mammography (CEM), and molecular breast imaging (MBI), each section delves into the principles of operation, technical specifications, optimal usage scenarios, and clinical applications of the equipment.

Designed for radiologists, breast surgeons, oncologists, technologists, and trainees alike, this guide balances the theoretical underpinnings with practical, evidence-based insights. Emphasis is placed on adherence to current international guidelines—such as those by ACR, NCCN, and EUSOBI—while highlighting the nuances in imaging protocols, patient preparation, and interpretation criteria. Special attention is given to image-guided procedures, emerging technologies, and the role of artificial intelligence in enhancing diagnostic accuracy and workflow efficiency.

As breast imaging continues to evolve, a thorough understanding of the available modalities and their optimal usage remains essential to delivering high-quality, patient-centered care. This chapter aims to serve as both a foundational text and a reference point for continuous clinical excellence.

Types of Breast Imaging Modalities

1.Mammography

- ✓ Conventional 2D Digital Mammography (DM)
- ✓ Digital Breast Tomosynthesis (DBT) – 3D mammography
- ✓ Contrast-Enhanced Mammography (CEM) – combines iodine contrast with mammography[4]

2.Breast Ultrasound

- ✓ Hand-Held Ultrasound (HHUS) – widely used for diagnostic purposes
- ✓ Automated Breast Ultrasound System (ABUS) – used for supplemental screening in dense breasts
- ✓ Elastography – evaluates tissue stiffness

3.Breast Magnetic Resonance Imaging (MRI)

✓ Contrast-Enhanced MRI (CE-MRI) – for high-risk screening, staging, and therapy monitoring
✓ Diffusion-Weighted Imaging (DWI) – non-contrast functional imaging
✓ MR Spectroscopy – under research; evaluates biochemical tissue profile

4.Molecular Breast Imaging (MBI) / Nuclear Medicine [3,4]

✓ Scintimammography
✓ Positron Emission Mammography (PEM)
✓ Single Photon Emission Computed Tomography (SPECT) – rarely used

5.Thermography[3] **(Infrared Imaging)**

✓ Non-ionizing technique; lacks standardization and not recommended for routine use by major guidelines

6.**Optical Imaging (Emerging/Experimental)**

✓ Includes diffuse optical tomography and near-infrared spectroscopy

7.Photoacoustic Imaging (research setting)

✓ Combines ultrasound and laser-induced imaging; potential future role in lesion characterization

8.Image-Guided Interventions

✓ Ultrasound-guided biopsy
✓ Stereotactic-guided biopsy (mammography)
✓ MRI-guided biopsy

Breast Cancer Risk Classification :

Breast cancer risk classification is a systematic approach to stratify individuals based on their likelihood of developing breast cancer. It guides decisions related to screening, genetic counseling, lifestyle counseling, and preventive interventions.
The classification is typically divided into three categories:

🔹 1. Average Risk

No personal or strong family history of breast or ovarian cancer
No known genetic mutations (e.g., BRCA1/BRCA2)
No prior chest radiation therapy
No history of atypical hyperplasia or LCIS

🔸 2. Moderate/Intermediate Risk

Family history (but no known mutation)
Dense breast tissue (BI-RADS C or D)15
History of atypical ductal / lobular hyperplasia or LCIS
Estimated lifetime risk 15–20%

3. High Risk

Known pathogenic gene mutation (e.g., BRCA1, BRCA2, TP53, PTEN)
First-degree relative with a known mutation (even if patient not tested)
History of chest radiation between ages 10–30
Personal history of early-onset or bilateral breast cancer
Estimated lifetime risk ≥20–25% (based on models like Tyrer-Cuzick or BOADICEA)

RISK ASSESMENT MODELS:

MODEL	PURPOSE	NOTES
Gail Model	Estimates 5-year/lifetime risk	Best for average risk women
Tyrer-Cuzick (IBIS)	Detailed model using family/genetic data	Preferred for high-risk screening eligibility
BOADICEA	Includes extended family/genetics	Often used in genetics clinics

1. MAMMOGRAPHY:

Modality: Digital Mammography (DM) or Digital Breast Tomosynthesis (DBT)
Indication:

Screening - Annual screening mammography is recommended beginning at age 40 for women at average risk[1]

Diagnostic - For evaluation of breast symptoms (e.g., palpable lump, nipple discharge), abnormal screening results, or post-treatment surveillance.

Equipment: Systems must meet the MQSA (Mammography Quality Standards Act) requirements.
DBT is preferred over 2D alone due to better cancer detection and lower recall rates.

Interpretation:
ACR BI-RADS® 5th edition should be used for structured reporting[1,5]
Screening Mammography (with Tomosynthesis) : Recommended for average- and increased-risk individuals; tomosynthesis improves detection and reduces recall rates. (NCCN 2023)

2. BREAST ULTRASOUND:

Modality: Hand-held or Automated Breast Ultrasound (ABUS)
Indication:

- Evaluation of palpable abnormalities or areas of concern found on mammography.
- Supplemental screening for women with dense breast tissue[2,3](NCCN)
- Guidance for biopsies and cyst aspiration.

Equipment: High-frequency linear array transducers (minimum 12 MHz recommended).
Interpretation:

- Structured reporting via BI-RADS with documentation of lesion characteristics (shape, orientation, margin, echo pattern).[1,5]

3. BREAST MRI
Modality: Contrast-Enhanced Breast MRI (CE-MRI)[3,4]

Indication:
High-risk screening (e.g., BRCA mutation carriers, lifetime risk >20–25%).
Preoperative staging of known breast cancer.
Evaluation of response to neoadjuvant chemotherapy.
Problem-solving when other imaging is inconclusive.

Equipment:
Dedicated breast coil (minimum 1.5T MRI with at least 4-channel coil).
Protocol must include pre- and post-contrast T1-weighted imaging with subtraction and dynamic sequences.

Guidance:
MRI-guided biopsy capability should be available when offering diagnostic MRI.

4. CONTRAST-ENHANCED MAMMOGRAPHY (CEM)
Status: Emerging modality, ACR supports its use with proper training and QA.

Indication:
Problem-solving in dense breasts or when MRI is contraindicated.
Pre-surgical evaluation and cancer staging.

Consideration: Should follow similar protocols to CE-MRI in terms of contrast handling and safety

5. MOLECULAR BREAST IMAGING (MBI) / NUCLEAR MEDICINE
Status: Optional adjunct for problem-solving and high-risk screening.

Use: May be used in specific cases, such as dense breasts, but not recommended for routine screening.

Caution: Due to radiation exposure, ACR emphasizes judicious use.

6. IMAGE-GUIDED INTERVENTIONS

Techniques:
Stereotactic biopsy (mammography-guided)
Ultrasound-guided biopsy
MRI-guided biopsy

Requirements:
Radiologist must be proficient in modality-specific interventions.
Documentation and real-time correlation with imaging findings are mandatory.
Tissue marker placement should be done post-biopsy.

7. REPORTING STANDARDS

BI-RADS System (2023 Update):[1,5]
All breast imaging reports (mammography, ultrasound, MRI) must use the BI-RADS categories (0–6).[1,5]
Include breast density (A–D classification).
Recommendations must be clear, consistent with findings, and include follow-up intervals.
Breast Imaging-Reporting and Data System (BI-RADS®): 5th Edition[1,5]

BI-RADS Assessment[1,5] Categories :

Category	Definition	Likelihood of Malignancy	Management
0	Incomplete – additional imaging required	N/A	Recall for further evaluation
1	Negative – no abnormal findings	0%	Routine screening
2	Benign finding (e.g., cyst, fibroadenoma, calcified fibroadenoma, fat necrosis)	0%	Routine screening
3	Probably benign	<2%	Short-interval follow-up (typically 6 months)
4 Low suspicion – 4A Moderate suspicion – 4B High suspicion – 4C	Suspicious abnormality	2–95% >2–10% >10–50% >50–95%	Biopsy recommended Biopsy Biopsy Biopsy

5	Highly suggestive of malignancy	>95%	Appropriate action (biopsy/surgery)
6	Known biopsy-proven malignancy	100%	Ensure appropriate treatment

There are four standardized breast density categories:

Category	Description	Old ACR Term	Clinical Significance
A	**Almost entirely fatty**	ACR 1	Very little fibroglandular tissue; mammography is most sensitive in these patients.
B	**Scattered areas of fibroglandular density**	ACR 2	Some scattered density but still relatively easy to detect abnormalities.
C	**Heterogeneously dense**	ACR 3	May obscure small masses; reduced mammographic sensitivity.
D	**Extremely dense**	ACR 4	Can lower the sensitivity of mammograms significantly and is associated with increased breast cancer risk.

8. QUALITY ASSURANCE & TRAINING

Facilities must maintain: Credentialing, peer review, and audit systems.
Regular equipment calibration and technologist training.
Radiologists: Must meet CME requirements in breast imaging.
Participation in audit programs (e.g., PPV, recall rate, cancer detection rate) is strongly advised.

Imaging Modalities Overview NCCN 2023

- Screening Mammography (with Tomosynthesis) : Recommended for average- and increased-risk individuals; tomosynthesis improves detection and reduces recall rates.
- Ultrasound (US) : Used as supplemental screening in women with dense breasts or when MRI is unavailable.
- Breast MRI (with and without contrast)[3,4] : Strongly recommended for those at high risk (≥20% lifetime risk, prior thoracic RT). Ideal protocols include dedicated coil, expert radiologist, ability for MRI-guided biopsy. MRI may alternate with mammography every 6 months.
- Contrast-Enhanced Mammography (CEM)[4] : Optional alternative when MRI cannot be done.
- Molecular Breast Imaging (MBI) (e.g., [3,4]scintimammography / breast-specific gamma imaging) : Another alternative when MRI is contraindicated or unavailable.
- Imaging to Avoid : Thermography[3] and ductal lavage are not recommended for screening or diagnosis.

Risk Level Recommended Imaging Modalities:

Average risk (≥40 years)

Annual screening mammogram with tomosynthesis; consider supplemental imaging for dense breasts.

Increased risk (Gail ≥1.7%)

Annual mammogram with tomosynthesis; annual MRI (w/ & w/o contrast); or CEM/MBI/US if MRI not feasible.

Prior thoracic RT

Screening starting 8–10 years post-RT but not before age 25; includes annual mammogram (with tomosynthesis) plus MRI or alternatives if needed.

Diagnostic Workflow & Follow-up:

When abnormalities arise (e.g., BI-RADS 4 or 5), the standard work-up includes:[1,5]

- ✓ Diagnostic mammogram (with tomosynthesis) + ultrasound,
- ✓ Core needle biopsy (preferred),
- ✓ MRI or specialist consultation as needed.
- ✓ For benign or indeterminate findings (e.g., BI-RADS 1–3 with clinical suspicion, ADH/LCIS discrepancies), follow-up may include imaging at 6–12 months, surgical excision, or continued surveillance per risk. [1,5]

References

1. American College of Radiology. ACR Practice Parameter for the Performance of Screening and Diagnostic Mammography. Reston (VA): ACR; 2023. Available from: https://gravitas.acr.org/PPTS/GetDocumentView?docId=8

2. American College of Radiology. ACR Practice Parameter for the Performance of Whole-Breast Ultrasound for Screening and Staging. Reston (VA): ACR; 2024. Available from: https://gravitas.acr.org/PPTS/DownloadPreviewDocument?DocId=61&ReleaseId=2

3. Monticciolo DL, Mainiero MB, Moy L, Lee SJ, Morris EA, Monsees B, et al. ACR Appropriateness Criteria® Breast Cancer Screening. J Am Coll Radiol. 2024; PMID: 38823941.

4. Moy L, Morris EA, Lee SJ, Monticciolo DL, Monsees B, Mainiero MB, et al. ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer. J Am Coll Radiol. 2024. Available from: https://www.jacr.org/article/S1546-1440(24)00262-X/fulltext

5. American College of Radiology. Practice Parameters and Technical Standards Overview. Reston (VA): ACR; 2023. Available from: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Practice-Parameters-and-Technical-Standards

07 Medical Devices for Breast Biopsy

Author- Dr Archana Singh
FICOG Fellowship in reproductive medicine (Germany),
Fellowship in Day Care Endoscopy
Hyderabad

1. Introduction

Breast biopsy is the **definitive diagnostic step** for suspicious breast lesions detected by imaging (mammography, ultrasound, MRI). With cytology such as FNA insufficient to distinguish in situ from invasive cancer, histologic samples obtained via core or vacuum-assisted methods .

The two primary **minimally invasive** approaches are

- **Core Needle Biopsy (CNB)** — spring-loaded automated core sampling
- **Vacuum-Assisted Breast Biopsy (VABB)** — suction-assisted contiguous sampling

2. Fine-Needle Aspiration (FNA)

FNA uses a thin (≈20-22 G) needle to aspirate cells for cytology. It's minimally invasive and fast but lacks architectural detail. It is now chiefly used for cyst fluid evacuation or in settings where histology is less critical. FNA is generally inferior to CNB and VABB when diagnostic certainty is required.

3. Core Needle Biopsy (CNB)

3.1 Device Design & Needle Sizes

CNB typically employs a spring-loaded "biopsy gun" with a hollow needle featuring a side-slot trough. The spring deploys a cutting sheath, capturing a cylindrical core of tissue The standard gauge is 14 G, balancing diagnostic yield and invasiveness; smaller 16–18 G needles may be used for fragile or small lesions.

3.2 Sample Strategy

For palpable masses, 4–6 cores are typically sufficient; for microcalcifications, up to 10 cores may be needed to minimize sampling error.

3.3 Imaging Guidance

- **Ultrasound-guided CNB** is first-line when lesions are sonographically visible—quick, real-time targeting, and lower cost.
- **Stereotactic (mammography-guided) CNB** is reserved for lesions seen as calcifications or subtle distortions not visible on ultrasound.
- **MRI-guided CNB** applied for MRI-only detected abnormalities, using MRI-compatible needles.

3.4 Advantages & Limitations

Advantages:

- Good diagnostic accuracy (sensitivity > 90 %)
- Lower bleeding risk than larger devices
- Widely accessible and cost-effective
-

Limitations:

- Smaller tissue volume than VABB → higher underestimation risk, especially for ductal atypia or DCIS
- Multiple insertions may cause patient discomfort
- Sampling error rates (e.g. false-negative/underestimation) approximately 5–10 %

4. Vacuum-Assisted Breast Biopsy (VABB)

4.1 Device Mechanism & Needle Selection

VABB systems draw tissue into a lateral window using vacuum suction; a rotating cutter then excises contiguous samples through one skin puncture. Common gauges:

- **14 G** (hand-held pseudo-VABB)
- **11 G** (moderate volume)
- **8 G** (largest volume; may fully excise lesions ≤ 3 cm)

4.2 Common Systems

Examples of VABB systems include Mammotome (8–11 G console), Hologic ATEC, Celero, and Bard Vacora (hand-held 14 G pseudo-vacuum).

4.3 Sample Strategy

Operators typically obtain 12 or more contiguous samples, aiming to remove approximately 1 cm^2 tissue — comparable to a sugar cube in volume.

4.4 Indications

Preferred in situations where larger tissue retrieval improves diagnostic certainty:

- **Microcalcifications**, especially BI-RADS B3 lesions (e.g. ADH, radial scars)
- Small palpable or non-palpable lesions amenable to near-complete excision
- When CNB histology is discordant with imaging findings
- MRI-only lesions using MRI-compatible VABB 1

4.5 Diagnostic Accuracy & Safety

- Sensitivity often > 96%, specificity near 100%, negative predictive value ~97%, accuracy ~98% in institutional series. 1
- DCIS underestimation rates around 4%; lower than with CNB 1
- Slightly higher rates of hematoma formation, especially with larger gauges, but major complications are rare 1

5. Comparative Overview: CNB vs VABB

5.1 Sample Yield & Diagnostic Confidence

- CNB (≈4 mm cores) yields limited tissue → higher sampling error in heterogeneous lesions.
- VABB with large-gauge probes provides 10× more tissue, reducing underestimation and improving diagnostic confidence (e.g. in B3 pathology).

5.2 Procedural Complexity & Costs

- CNB is faster, requires simpler setup, and is more economical.
- VABB systems (console or hand-held) are costlier and demand operator training.

5.3 Complication Risks

- CNB has lower bleeding and hematoma rates.
- VABB may cause more bruising and minor post-procedure bleeding, though serious complications are uncommon.

5.4 Application Based on Lesion Type

- **Ultrasound-visible mass** → CNB (14 G) preferred.
- **Small lesion or B3 pathology** → VABB (11–8 G).
- **Microcalcifications on mammogram only** → stereotactic VABB.
- **MRI-detected lesion only** → MRI-compatible CNB or VABB.

6. Practice Guidelines & Recommendations

6.1 Chinese Society of Breast Surgery (2021)

Recommends ultrasound-guided VABB as an effective and economical choice, noting its safety and real-time lesion monitoring without radiation 2

6.2 Chinese Neoadjuvant Therapy Guidelines (2024)

Expert panel (grade IA evidence) emphasizes that histologic diagnosis of breast lesions by CNB or VABB is mandatory prior to neoadjuvant therapy. They recommend clip placement for lesion localization and confirm imaging-pathology concordance before treatment decisions3.

6.3 US Accreditation Standards & Billing Updates

- As of April 2025, the American College of Radiology requires standardized labelling (e.g. “pre-fire,” “post-biopsy”) on ultrasound-guided biopsy images.

6.4 Regulatory Updates

In the US, amendments to the Mammography Quality Standards Act (MQSA) took effect September 10, 2024. Facilities must meet updated reporting criteria including lesion categorization and marker documentation.

7. Structured Procedural Workflow

7.1 Pre-Procedure Planning

- Review imaging and select modality: ultrasound, stereotactic, or MRI.
- Confirm lesion visibility and appropriate device availability (CNB vs VABB).
- Ensure anticoagulation status and allergy screen.
- Obtain informed consent, covering risks, biopsy strategy, and marker placement.

7.2 Procedure Outline (VABB as Example)

1. Position patient and sterilely prepare the site.
2. Administer local anesthesia.
3. Make small skin incision.
4. Insert VABB probe; align sampling aperture within target.
5. Activate vacuum and cutter; collect contiguous samples.
6. Take enough passes to achieve volume ~1 cm^2.
7. Deploy localization clip.
8. Post-procedure compression and dressing.
9. Obtain immediate imaging to confirm marker position (especially for stereo/MRI-guided

7.3 Tissue Handling

- Place cores flat on sponges in cassettes; maintain orientation.
- Label with modality, gauge, and lesion type.
- Ensure histopathology receives appropriate fixative and orientation notes.

7.4 Imaging-Pathology Correlation

- Mandatory in cases of discordance (e.g. benign CNB result for BI-RADS 5 lesion) to consider repeat biopsy or surgical excision.

Follow-up may be indicated if imaging and pathology do not align

8. Complications & Risk Management

8.1 Bleeding / Hematoma

- VABB associated with increased hematoma risk, especially with ≥11 G probes.
- Hematomas are usually minor; firm compression and post-procedure instructions suffice.

8.2 Pain and Infection

- Mild discomfort common; severe pain or infection rare.
- Use of local anesthesia effective; prophylactic antibiotics not routinely indicated. Sterile technique is essential.

8.3 Sampling Error / Underestimation

- CNB underestimation for ADH/DCIS up to 10% or more.
- VABB reduces underestimation but does not eliminate it.
- Papillary lesions, radial scars, or atypical hyperplasia may require excision if core/VABB findings are inconclusive.4

9. Emerging Tools & Future Directions

9.1 Robotic Motorized MRI-Guided Devices

Hand-mounted needle-steering platforms under development target MRI-visible lesions with accuracy near 2.3 mm, addressing manual targeting limitations.

9.2 AI-based Virtual Biopsy (Emerging)

Deep-learning models trained on mammography, ultrasound, and CESM are showing promise for non-invasive lesion characterization, but are still under investigation and not yet clinical standard.5

10. Reference List

1. Ultrasound-guided breast biopsies and indications ScienceDirect

2. Mammography-guided biopsy methods: CNB and VABB PMC

3. CNB superiority to FNA in diagnostic yield Bohrium

4. Chinese expert guideline endorsing ultrasound-guided VABB use mednexus.org

5. Chinese neoadjuvant therapy guidelines recommending CNB/VABB pre-treatment and clip marking Lippincott

----------XXXXXX----------

08 Innovations in Surgical Equipment for Breast Surgery

Author- Dr Monica Umbardand
Consultant Mangalya Nursing Home
and Atharva Fertility Centre, Solapur

Introduction

The landscape of breast surgery has evolved dramatically over recent decades, driven by ground-breaking innovations in surgical equipment, techniques, and patient-focused care protocols. These changes have transformed outcomes for patients facing both oncological and reconstructive breast surgeries. For gynaecologists in India, understanding these advancements is crucial, given the unique socio-economic factors, evolving guidelines, and resource settings that characterize Indian healthcare.

This chapter explores the latest innovations in surgical equipment for breast surgery, highlights consensus guideline recommendations, and contextualizes these within the Indian scenario.

Global Innovations in Breast Surgery Equipment

1. Minimally Invasive and Robotic Surgery

Modern breast surgery is increasingly emphasizing minimally invasive approaches. The introduction of surgical robots, such as the Senhance® and Versius® systems, has revolutionized precision and ergonomics. These platforms offer several advancements:

- **Haptic feedback and eye-tracking**: These features provide enhanced control and visualization, vital for complex dissections and delicate structures.
- **Miniaturization**: The compact design allows usage even in constrained operating rooms, which is highly relevant in resource-limited settings.
- **Portability**: Mobile robotic systems can be moved between operating theatres, maximizing utilization.

Robotic-assisted mastectomy and nipple-sparing mastectomy (NSM) are emerging as game-changers, with documented lower rates of nipple necrosis and improved cosmetic outcomes.

2. Advanced Imaging and Navigation

Innovations in intraoperative imaging have transformed breast conservation surgery:

- **Intraoperative Ultrasound & MRI**: Offer real-time delineation of tumour margins, improving accuracy and reducing re-excision rates.
- **Near-infrared fluorescence imaging**: Enables sentinel lymph node identification, reducing morbidity versus traditional axillary clearance.
- **3D Imaging Platforms**: Preoperative and intraoperative 3D visualization guides surgical planning and enhances cosmetic symmetry.

3. Vacuum-Assisted and Percutaneous Systems

Vacuum-assisted breast biopsy (VABB) and excision devices are gaining popularity, especially for benign lesions and small cancers.

- Minimal scarring and faster recovery.
- Outpatient feasibility.
- Greater patient acceptability, with significant traction in major Indian urban centers.

4. Oncoplastic and Reconstruction Innovations

Surgical equipment facilitating oncoplastic techniques allows wider excision with preservation of breast shape:

- **Mammotome and EnCor® devices:** Allow targeted, minimally disruptive excision.
- **Skin- and nipple-sparing mastectomy tools:** Specialized retractors, dermal closure devices, and advanced haemostatic materials are improving both oncological and cosmetic outcomes.
- **Prepectoral mesh and bio-absorbable matrices:** Facilitate immediate implant-based reconstruction, with rapid postoperative recovery.

5. 3D Printing and Personalized Implants

3D printing has enabled the creation of patient-specific breast implants and surgical guides:

- **Custom-fit implants:** Reduce complications and improve cosmetic results.
- **Preoperative simulation:** Surgeons can anticipate technical challenges, reducing intraoperative surprises.

6. Improved Anaesthesia and Recovery Protocols

- **Local and sedation-based anaesthesia:** Modern protocols favour local blocks and conscious sedation, reducing risks in vulnerable populations—an important consideration for India's diverse patient base.
- **Enhanced Recovery After Surgery (ERAS) protocols**: Focus on multimodal analgesia, early mobilization, and reduced hospital stay.

Key International Guidelines

American Society of Breast Surgeons (ASBrS) Consensus

The ASBrS emphasizes:

- Minimally invasive biopsy and excision as standard practice.
- Oncoplastic techniques to improve outcomes and reduce reoperation.
- Routine intraoperative imaging and multidisciplinary planning to optimize patient satisfaction and safety.
- Measurement of patient-reported outcomes as a quality metric.

FIGO & ESSO Recommendations

- **FIGO 2022/2023:** Innovations in management of breast tumours, especially early identification and minimally invasive management, tailored to LMIC needs, are highlighted.

- **ESSO 2022:** Stresses the importance of surgical quality indicators, multidisciplinary team (MDT) decisions, and the adoption of emerging technologies where feasible.

Indian Scenario: Adapting Innovations

Current Trends and Challenges

- **Rapid Uptake in Urban Centers**: Tertiary care hospitals in Delhi, Mumbai, Bengaluru, and Hyderabad have adopted robotic platforms and advanced imaging tools for breast surgery.
- **Limited Penetration in Tier 2/3 Cities**: Resource constraints and lack of specialized training inhibit widespread adoption of these innovations in smaller cities.
- **Cost Considerations**: Out-of-pocket payment models still dominate in India; hence, cost-effectiveness and turnaround time are critical determinants of adoption.

Innovations Gaining Traction in India

1. Vacuum-Assisted Breast Surgery

India is witnessing a surge in vacuum-assisted techniques for both diagnostic and therapeutic effusions, such as excising fibroadenomas and papillomas with minimal recovery time. This technique is especially popular among younger patients and for day-care procedures.

2. Oncoplastic Surgery Evolution

- **Slow Acceptance:** But now considered a "standard of care" in large Indian oncology centers for eligible early breast cancer cases.
- **Training Initiatives:** More fellowships and workshops in oncoplastic breast surgery are being offered annually.

3. Robotic Surgery

- **Successful Implementation:** Pioneered in centers like Apollo Hospitals, these techniques are now being used for robotic nipple-sparing mastectomy and axillary surgeries, with improved outcomes.
- **Challenge:** Cost and the need for specialized surgical teams remain barriers to wider diffusion.

4. 3D Printing and Custom Prosthetics

- **Patient-Specific Solutions:** 3D-printed guides and implants are being piloted in selected reconstructive cases, offering hope for more individualized options in future.

5. Advanced Implants

The new generation of breast implants, featuring thinner, more durable shells and personalized sizing, is emerging as a preferred choice among Indian patients seeking both reconstruction and cosmetic augmentation, with enhanced naturalness and reduced complications.

Case Reflections & Unique Indian Considerations

Socio-Economic Factors

- **Disparities in Access:** Tier 1 hospitals offer cutting-edge technology, while district hospitals often rely on traditional methods.
- **Public versus Private:** Public hospitals face cost and procurement challenges but play a vital role in reaching rural populations.

Cultural Sensitivity

- **Awareness and Acceptance:** Many patients are unaware of options such as oncoplastic or minimally invasive approaches because of lack of referral, education, or conservative attitudes towards breast surgery.
- **Cosmetic Outcomes:** There is a growing focus on post-surgical appearance and quality of life, particularly among younger urban women, increasing demand for advanced reconstructive options.

Patient-Centered Care

- **Emphasis on Reduced Morbidity:** Techniques that prioritize less invasiveness and quicker recovery are especially valuable given the economic impact of extended hospitalization for Indian families.
- **Rise in Day-Care Surgeries:** Outpatient or short-stay breast procedures improve efficiency, reduce costs, and benefit the patient experience.

The Way Forward: Recommendations for Practitioners

- **Adopt evidence-based innovations** that fit local resources and patient needs.
- **Prioritize multidisciplinary planning**, including team-based decision-making for surgical strategy.
- **Invest in training** for advanced techniques among surgeons and supporting staff.
- **Engage in patient education** initiatives to raise awareness of new surgical options and their benefits.
- **Advocate for healthcare policies** that support the procurement and dissemination of advanced equipment, especially in public healthcare facilities.

Conclusion

The future of breast surgery is defined by precision, personalization, and reduced invasiveness. Indian practitioners are increasingly integrating robotic surgery, vacuum-assisted excision, 3D printing, and advanced imaging into their clinical practice, especially in major urban centers. Cost-effective, resource-appropriate deployment of these innovations, alongside strong guideline adherence and patient-centered care, will drive the next decade of progress in breast surgical oncology and reconstructive care in India.

References

1.Crystal J, et al. Current Surgical Innovations in the Treatment of Breast Cancer. StatPearls [Internet]. 2022 [cited 2025 Jul 23].

2.Jain Y, et al. Revolutionising Breast Surgery: A Comprehensive Review of Robotic-Assistive Technology. Cureus. 2024;16(1):e54218.

3.Gomés R. New technologies and innovations in breast surgery. Rev Bras Cir Plást. 2001;16(1):1-6.

- 4.Mission Surgical. Latest Advances in Breast Cancer Surgery Techniques 2024 [Internet]. 2025 [cited 2025 Jul 23].
- 5.Neonest. Integrating Technology In Breast Surgery: Advancements and Applications. 2024[cited 2025 Jul 23].
- 6.BreastHealth.in. Is Vacuum-Assisted Breast Surgery a New Surgical Approach Gaining Popularity in India? 2024[cited 2025 Jul 23].
- 7.Dr Jack Peterson. New Breast Augmentation Methods in 2025. 2025 Feb 6[cited 2025 Jul 23].
- 8.Landercasper J, et al. Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcomes: The American Society of Breast Surgeons (ASBrS) Consensus Conference. Ann Surg Oncol. 2015;22(2):393-401.
- 9.N Maggi et al. The American Society of Breast Surgeons classification... Surgery. 2023.
- 10.PMC. The new FIGO 2023 staging reclassification of patients with FIGO...
- 11.Medanta. Robotic-assisted Mastectomy & Breast Reconstruction. 2025 Mar 17.
- 12.Apollo Hospitals. India's First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka's 1st Robotic Nipple-Sparing Mastectomy. [cited 2025 Jul 23].
- 13.Jain Y, et al. Breast conservation surgery & oncoplasty in India – Current scenario. Indian J Surg Oncol. 2022;13:25-31.
- 14.Dr Jack Peterson. Latest Breast Implant Technology in 2025: What's New? 2025 Mar 24[cited 2025 Jul 23].
- 15.ESMO Clinical Practice Guidelines: Breast Cancer.
- 16.PMC. FIGO 2023 endometrial staging: a leap of faith into the new... 2024.
- 17.DrJayanam.com. Cutting-Edge Innovations in Breast Cancer Surgery. 2024 Aug 13.
- 18.Plastic Surgery.org. What's on the horizon? Plastic surgery trends for 2025. 2025 Jan 10.
- 19.The American Society of Breast Surgeons. Official Statements. 2024 Oct 2.

9 Sterilization and Infection control in breast procedures

Author - Dr Shikha Sachan
Dept of obst & Gyne, IMS BHU
Varanasi UP

Disinfection and sterilization are essential for ensuring that medical and surgical instruments do not transmit infectious pathogens to patients. Because sterilization of all patient-care items is not necessary, health-care policies must identify, primarily on the basis of the items' intended use, whether cleaning, disinfection, or sterilization is indicated.

Sterilization describes a process that destroys or eliminates all forms of microbial life and is carried out in health-care facilities by physical or chemical methods. Steam under pressure, dry heat, EtO gas, hydrogen peroxide gas plasma, and liquid chemicals are the principal sterilizing agents used in health-care facilities. The concept of what constitutes "sterile" is measured as a probability of sterility for each item to be sterilized. This probability is commonly referred to as the sterility assurance level (SAL) of the product and is defined as the probability of a single viable microorganism occurring on a product after sterilization. SAL is normally expressed a 10^{-n}. For example, if the probability of a spore surviving were one in one million, the SAL would be 10^{-6}.[1,2]

Different methods of sterilization:

Sterilization Method	Advantages	Disadvantages
Steam	• Nontoxic to patient, staff, environment • Cycle easy to control and monitor • Rapidly microbicidal • Least affected by organic/inorganic soils among sterilization processes listed • Rapid cycle time • Penetrates medical packing, device lumens	• Deleterious for heat-sensitive instruments • Microsurgical instruments damaged by repeated exposure • May leave instruments wet, causing them to rust • Caution: Potential for burns

Hydrogen Peroxide Gas Plasma	• Safe for the environment • Leaves no toxic residuals • Cycle time is 28-75 minutes (varies with model type) and no aeration necessary • Used for heat- and moisture-sensitive items since process temperature <50°C • Simple to operate, install (208 V outlet), and monitor • Compatible with most medical devices • Only requires electrical outlet	• Cellulose (paper), linens and liquids cannot be processed • Sterilization chamber size from 1.8-9.4 ft3 total volume (varies with model type) • Some endoscopes or medical devices with long or narrow lumens cannot be processed at this time in the United States (see manufacturer's recommendations for internal diameter and length restrictions) • Requires synthetic packaging (polypropylene wraps, polyolefin pouches) and special container tray • Caution: Hydrogen peroxide may be toxic at levels greater than 1 ppmTWA
100% Ethylene Oxide (ETO)	• Penetrates packaging materials, device lumens • Single-dose cartridge and negative- pressure chamber minimizes the potential for gas leak and ETO exposure • Simple to operate and monitor • Compatible with most medical materials	• Requires aeration time to remove ETO residue • Sterilization chamber size from 4.0-7.9 ft3 total volume (varies with model type) • ETO emission regulated by states but catalytic cell removes 99.9% of ETO and converts it to CO2 and H2O • ETO cartridges should be stored in flammable liquid storage cabinet • Lengthy cycle/aeration time • Caution: ETO is toxic, a carcinogen, and flammable
ETO Mixtures 8.6% ETO/91.4% HCFC 10% ETO/90% HCFC 8.5% ETO/91.5% CO2	• Penetrates medical packaging and many plastics • Compatible with most medical materials • Cycle easy to control and monitor	• Some states (e.g., CA, NY, MI) require ETO emission reduction of 90-99.9% • Chlorofluorocarbon (CFC) (inert gas that eliminates explosion hazard) banned in 1995 • Potential hazards to staff and patients • Lengthy cycle/aeration time • Caution: ETO is toxic, a carcinogen, and flammable

Peracetic Acid	• Rapid cycle time (30-45 minutes) • Low temperature (50-55°C) liquid immersion sterilization • Environmental friendly by-products • Sterilant flows through endoscope which facilitates salt, protein and microbe removal	• Point-of-use system, no sterile storage • Biological indicator may not be suitable for routine monitoring • Used for immersible instruments only • Some material incompatibility (e.g., aluminum anodized coating becomes dull) • One scope or a small number of instruments processed in a cycle • Caution: Potential for serious eye and skin damage (concentrated solution) with contact

Disinfection describes a process that eliminates many or all pathogenic microorganisms, except bacterial spores, on inanimate objects. In health-care settings, objects usually are disinfected by liquid chemicals or wet pasteurization. Each of the various factors that affect the efficacy of disinfection can nullify or limit the efficacy of the process.

Methods of Disinfection

Chemical Disinfectants

- Alcohol
- Chlorine and chlorine compounds
- Formaldehyde
- Glutaraldehyde
- Hydrogen peroxide
- Iodophors
- Ortho-phthalaldehyde (OPA)
- Peracetic acid
- Peracetic acid and hydrogen peroxide
- Phenolics
- Quaternary ammonium compounds

Miscellaneous Inactivating Agents

- Other germicides
- Metals as microbicides
- Ultraviolet radiation
- Pasteurization
- Flushing- and washer-disinfectors

Cleaning:

Cleaning is the removal of foreign material (e.g., soil, and organic material) from objects and is normally accomplished using water with detergents or enzymatic products. Thorough cleaning is required before high-level disinfection and sterilization because inorganic and organic materials that remain on the surfaces of instruments interfere with the effectiveness of these processes. Also, if soiled materials dry or bake onto the instruments, the removal process becomes more difficult and the disinfection or sterilization process less effective or ineffective. Surgical instruments should be pre-soaked or rinsed to prevent drying of blood and to soften or remove blood from the instruments. The most common types of mechanical or automatic cleaners are ultrasonic cleaners, washer-decontaminators, washer-disinfectors, and washer-sterilizers. For instrument cleaning, a neutral or near-neutral pH detergent solution commonly is used because such solutions generally provide the best material compatibility profile and good soil removal. Enzymes, usually proteases, sometimes are added to neutral pH solutions to assist in removing organic material. Enzymes in these formulations attack proteins that make up a large portion of common soil (e.g., blood, pus). Cleaning solutions also can contain lipases (enzymes active on fats) and amylases (enzymes active on starches). Enzymatic cleaners are not disinfectants, and proteinaceous enzymes can be inactivated by germicides. [3,4]

Sterilization and infection control are critical components in breast procedures, whether cosmetic (e.g., augmentation, reduction, lift) or medically necessary (e.g., biopsies, mastectomies, reconstructive surgeries). Proper protocols help reduce the risk of surgical site infections (SSIs), improve healing outcomes, and ensure patient safety.

1. Preoperative Measures

Patient Preparation

- **Skin cleansing**: Patients are typically instructed to bathe with antiseptic agents (e.g., chlorhexidine) the night before and morning of surgery.
- **Hair removal**: If needed, use clippers instead of razors to reduce microabrasions.
- **Preoperative antibiotics**: Given 30–60 minutes before incision (usually a first-generation cephalosporin like cefazolin).

Assessment of Risk Factors

- Diabetes, obesity, smoking, immunosuppression, prior radiation, or recent infections can increase the risk of SSIs and should be optimized preoperatively.

2. Operating Room Sterility

Aseptic Technique

- **Sterile draping**: The surgical field must be draped using sterile technique to expose only the operative site.
- **Sterile instruments**: All surgical tools and implants (e.g., breast implants, expanders) are sterilized (usually with autoclaving or gas sterilization).
- **Surgeon preparation**: Includes thorough scrubbing, sterile gowning, and gloving.

Environmental Controls

- Laminar airflow systems and restricted OR access during procedures help maintain a sterile field.

Infection control in breast procedures:

An infection that occurs in surgical patients at the site of operation is known as surgical site infection. Surgical site infection accounts for about 15% of all health-care associated infections and about 37% of the hospital-acquired infections of surgical patients.[5,6] Two thirds of surgical site infections are incisional and one third confined to the organ space.[6] Surgical site infections lead to an average increase in the length of hospital stay of 4–7 days.

Infection does not occur in most patients because their innate host defences eliminate contaminants at the surgical site efficiently .[7]There are at least three important determinants of whether contamination will lead to surgical site infection: the dose of bacterial contamination, the virulence of the bacteria and the resistance of the patient.[8] This is demonstrated in the following formula[9]:

Dose of bacterial contamination x Virulence of bacteria = Risk of surgical site infection
Resistance of host

Other factors that affect the probability of infection are depicted in the following hypothetical equation [7]:

Inoculum of bacteria + Virulence of bacteria + Adjuvant effects = Probability of infection Innate and adoptive host defence – Acute and chronic host liabilities

The probability of infection increases proportionally as the number and virulence of the bacteria increase. Local characteristics of the wound, such as residual dead tissue, sutures or other foreign material or the presence of drains, will amplify the consequence of the bacterial inoculum.

Bacterial contamination is a necessary precursor to surgical site infection. Skin bacteria are always present, despite thorough skin preparation. In addition, numerous bacteria contaminate any operation involving a body structure ordinarily colonized by bacteria, such as the bowel. Quantitatively, the risk for surgical site infection is markedly increased if the surgical site is contaminated with > 105 microorganisms per gram of tissue [9]; however, the dose of contaminating microorganisms required to produce infection might be much lower when foreign material is present at the surgical site (e.g. 100 staphylococci per gram of tissue introduced on silk sutures).

Simple methods that can be used to limit risk include:

- Complete assessment of all surgical patients preoperatively;
- Reduced preoperative hospitalization;
- Evaluation and treatment of remote infections;
- Weight reduction (for obese patients);
- Cessation of tobacco use;
- Control of hyperglycaemia;

- Restoration of host defences;
- Decreased endogenous bacterial contamination;
- Appropriate methods of hair removal;
- Administration of appropriate and timely antimicrobial prophylaxis;
- Confirmation of proper asepsis and antisepsis of skin and instruments;
- Maintenance of meticulous surgical technique and minimization of tissue trauma;
- Maintenance of normothermia during surgery;
- Shortened operating time; and
- Effective wound surveillance

References:

1.Favero MS. Sterility assurance: Concepts for patient safety. In: Rutala WA, ed. Disinfection, sterilization and antisepsis: principles and practices in healthcare facilities. Washington, DC: Association for Professional in Infection Control and Epidemiology, 2001:110-9.

2.Oxborrow GS, Berube R. Sterility testing-validation of sterilization processes, and sporicide testing. In: Block SS, ed. Disinfection, sterilization, and preservation. Philadelphia: Lea & Febiger, 1991:1047-57.

3. Hutchisson B, LeBlanc C. The truth and consequences of enzymatic detergents. Gastroenterol. Nurs. 2005;28:372-6.

4. Zuhlsdorf B EM, Floss H, Martiny H,. Cleaning efficacy of nine different cleaners in a washer-disinfector designed for flexible endoscopes. J. Hosp. Infect. 2002;52:206-11.

5.Smyth ET, Emmerson AM. Surgical site infection surveillance. Journal of Hospital Infection, 2000;45:173–84.

6. Horan TC, et al. Nosocomial infections in surgical patients in the United States, January 1986–June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infection Control and Hospital Epidemiology, 1993;14:73–80.

7. Fry D. Surgical site infection: pathogenesis and prevention. Medscape Surgery, 2003. http://www.medscape.com/ clinicalupdate/ssi (accessed 20 October 2008).

8. . Cruse P. Surgical wound infection. In: Wonsiewicz M, ed. Infectious diseases. Philadelphia, W.B. Saunders, 1992:758–764.

9. Mangram AJ, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infection Control and Hospital Epidemiology, 1999;20:250–80.

10

Pharmacological Management of Mastalgia

Author:- Dr. Jyothi G. S.
MBBS, MD OBG, PGDMLE, FICOG, FICMCH Professor and Head,
Department of Obstetrics & Gynaecology,
Ramaiah Medical College & Hospitals,
Bengaluru 560054

Co- Author:- Dr. Varsha G.
MBBS, MS OBG
Senior Resident
Department of Obstetrics and Gynaecology,
Ramaiah Medical College and Hospitals,
Bengaluru 560054

Introduction

Mastalgia, or breast pain, is one of the most common complaints among women of reproductive age, with up to 70% experiencing it at some point in their lives. Though it is usually benign, it can significantly affect quality of life and contribute to anxiety, particularly due to the fear of underlying malignancy. Mastalgia is classified into three broad categories- cyclical, non-cyclical, and extramammary pain- each with different underlying aetiologies and treatment needs. While reassurance and lifestyle changes are often sufficient in mild cases, pharmacological interventions become necessary in moderate to severe or persistent mastalgia.

This article reviews the current pharmacological strategies used to treat mastalgia, based on globally recognized guidelines and recent clinical evidence, with special consideration for patient-centered, context-specific care.

Clinical Assessment and Classification

A thorough assessment is essential to determine the type and cause of mastalgia before starting treatment. Cyclical mastalgia is typically bilateral, diffuse, and synchronized with the menstrual cycle, affecting women aged 30-50. It is often hormonally mediated, peaking during the luteal phase. Non-cyclical mastalgia tends to be unilateral, localized, and not linked to the menstrual cycle. This form is more common in perimenopausal or postmenopausal women. Extramammary pain is caused by pathology outside the breast tissue such as costochondritis, chest wall trauma, or cervical radiculopathy.

A comprehensive history, physical examination, and appropriate imaging- such as ultrasonography or mammography depending on the patient's age and risk factors are crucial to rule out malignancy and guide management.

Conservative First-Line Measures

Before pharmacologic therapy is considered, most guidelines recommend conservative management for a trial period of at least 3-6 months. Supportive measures include wearing a well-fitting, supportive bra to reduce mechanical strain, dietary modifications such as reducing caffeine, salt, and saturated fats, and managing stress through mindfulness, yoga, or cognitive-behavioural techniques.

Nutritional supplements like evening primrose oil (containing gamma-linolenic acid) and vitamin E are often recommended, although the evidence remains inconsistent. However, due to their safety and accessibility, they are widely used as first-line adjunctive therapies. Patient education and reassurance remain the cornerstone of managing mild cases.

Pharmacological Treatment Options

For patients whose symptoms persist despite conservative measures, pharmacological therapies are introduced based on mastalgia type, symptom severity, and patient preference.

Danazol

Danazol is a synthetic androgen that inhibits pituitary gonadotropin secretion, thereby reducing estrogen levels. It is FDA-approved for the treatment of severe cyclical mastalgia and has demonstrated efficacy in about 70% of cases. Dosages range from 100–200 mg daily, often initiated during the luteal phase.

However, androgenic side effects like weight gain, acne, voice deepening, menstrual irregularities, and potential hepatotoxicity limit its use. Hence, it is typically prescribed for short durations under close supervision.

Tamoxifen

Tamoxifen, a selective estrogen receptor modulator (SERM), has been shown to reduce cyclical breast pain effectively at doses of 10–20 mg daily for 3–6 months. It works by modulating estrogen receptor activity in breast tissue. Tamoxifen offers a favorable efficacy profile with fewer androgenic side effects compared to danazol.

Nevertheless, risks like thromboembolism and endometrial hyperplasia require careful patient selection and monitoring. It is often reserved for women with severe mastalgia who have not responded to other treatments or those at high risk for breast pathology.

Bromocriptine

Bromocriptine, a dopamine receptor agonist, reduces prolactin secretion and is especially useful in women with hyperprolactinemia-associated mastalgia. A dose of 2.5 mg once or twice daily has shown symptomatic improvement. However, side effects like nausea, dizziness, and postural hypotension limit its acceptability.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Topical NSAIDs such as diclofenac or ketoprofen gels offer an effective, non-invasive treatment for localized breast pain. These can be applied two to three times daily and are generally well tolerated. Oral NSAIDs like ibuprofen and mefenamic acid are also effective for short-term relief, especially in non-cyclical mastalgia, but may cause gastrointestinal discomfort with prolonged use.

Oral Contraceptive Pills (OCPs)

Combined OCPs help stabilize hormonal fluctuations and can be beneficial in managing cyclical mastalgia. Some formulations may alleviate symptoms after 2-3 cycles, although others might exacerbate them. As such, they are best used in women seeking both contraception and relief from mild to moderate cyclical pain.

GnRH Analogues

Gonadotropin-releasing hormone (GnRH) analogues like leuprolide induce a reversible hypoestrogenic state by downregulating pituitary gonadotropins. Administered as a 3.75 mg monthly IM injection, these agents are potent but are limited by their high cost and adverse effects including menopausal symptoms and bone density loss. Their use should be restricted to short durations in severe refractory cases.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs such as fluoxetine and sertraline have shown promise in managing mastalgia, particularly in women with comorbid PMDD or depressive symptoms. Fluoxetine 20 mg or sertraline 50 mg daily can alleviate both emotional and somatic symptoms. While not first-line therapy for mastalgia, SSRIs can be a valuable adjunct in appropriate patients. Patient counseling about side effects like insomnia or gastrointestinal upset is important.

Centchroman (Ormeloxifene)

Centchroman is a non-steroidal SERM widely used in India for contraception. Anecdotal evidence and small clinical trials suggest that it may reduce mastalgia, especially when used cyclically. With a favorable side effect profile and accessibility in India, it holds potential as a cost-effective option pending further validation. The typical dosing is 30 mg twice a week for the first three months, followed by once-weekly maintenance.

Emerging and Adjunctive Therapies

Vitamin B6, magnesium supplements, and evening primrose oil have all been studied with mixed results. While these agents may benefit select patients, their role remains adjunctive. Diuretics have been used to alleviate premenstrual fluid retention but are not routinely recommended due to potential electrolyte disturbances.

Recent research into omega-3 fatty acids- particularly in fish oil formulations- has explored their anti-inflammatory potential in breast pain. Although results remain inconclusive, some women report improvement in symptoms with consistent use. Additionally, topically applied hormonal creams, like progesterone gel, have gained interest though more data is needed to support routine use.

Comparative Efficacy and Stepwise Approach

Comparative studies suggest tamoxifen and danazol are most effective in treating moderate to severe mastalgia, though they require close monitoring. NSAIDs and bromocriptine offer good results in specific contexts. A stepwise approach is widely recommended: beginning with reassurance, lifestyle changes, and local treatments, then escalating to systemic pharmacotherapy if symptoms persist. In cases where mastalgia significantly impacts psychological well-being, integrating mental health support is essential. Cognitive behavioral therapy (CBT), psychoeducation, and counseling can help address health anxiety and pain catastrophizing. Multidisciplinary management involving primary care providers, gynecologists, breast specialists, and psychologists ensures holistic care.

Clinicians must consider symptom type (cyclical vs. non-cyclical), severity, patient comorbidities, reproductive plans, and medication side-effect profiles when choosing therapy. Shared decision-making is key to improving adherence and outcomes.

India-Specific Considerations

In India, delayed presentation is common due to stigma, lack of awareness, and limited access to specialists. General practitioners and OB-GYNs should be trained to recognize and classify mastalgia early. Incorporating routine breast pain assessment during health check-ups can improve early intervention.

Patients may also seek alternative treatments such as Ayurveda or homeopathy. While clinicians should respect cultural practices, they should also guide patients toward evidence-based options, clarifying misconceptions and providing balanced counseling.

Affordability and availability of medications are additional concerns. Agents like centchroman, topical NSAIDs, and SSRIs may offer more accessible options in resource-limited settings.

Public health campaigns addressing breast health- including awareness about benign breast conditions—can help reduce anxiety and encourage timely care-seeking. Telemedicine consultations and online support groups may also serve as useful adjuncts in urban and rural settings.

Conclusion

Mastalgia, though often benign, can cause significant physical and emotional distress. An individualized, evidence-based approach is essential, beginning with conservative measures and escalating to pharmacological therapies when needed. Options like danazol, tamoxifen, bromocriptine, NSAIDs, SSRIs, and centchroman provide a diverse therapeutic arsenal.

As clinical understanding evolves, emerging therapies, personalized strategies, and collaborative, multidisciplinary approaches will enhance care. In the Indian context, early diagnosis, accessible interventions, and patient education are key to optimizing outcomes.

References

1. American Society of Clinical Oncology. Management of Breast Pain. ASCO Clinical Practice Guidelines. 2020.
2. Federation of Obstetric and Gynaecological Societies of India. Clinical Practice Recommendations for Mastalgia. FOGSI; 2021.
3. European Association of Urology, European Board of Urology. EAU/EBU Guidelines. 2020.
4. Cochrane Database of Systematic Reviews. Non-surgical interventions for breast pain (mastalgia).
5. Mansel RE, et al. A systematic approach to the treatment of breast pain. Br J Clin Pract. 1990;44(1):6–8.
6. Ader DN, Shriver CD. Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample. J Am Coll Surg. 1997;185(5):466–470.
7. Goyal A, Mansel RE. Mastalgia: current management. J R Soc Med. 2005;98(9):430–433.
8. Srivastava A, et al. Efficacy of Ormeloxifene in mastalgia: A clinical study. Int J Reprod Contracept Obstet Gynecol. 2015;4(6):1691–1694.
9. Davies EL, et al. The role of SSRIs in managing mastalgia. Breast J. 2013;19(3):256–260.
10. Lissoni P, et al. Use of tamoxifen and GnRH analogues in mastalgia. Oncology. 1995;52(3):222–225.

11 Hormonal Medications and Breast Disease: Risks & Benefits.

Author:- Dr. Prerna Saigal
MBBS, MD (Obs & Gyne) Kalyani
Hospital Pathankot, Punjab, India

INTRODUCTION :-

we use hormonal medications for a variety of breast conditions, mainly breast cancer. These hormonal medications interact with our body's natural hormones and hence create risk and benefits.

Types of Hormonal Medications

a)HRT It is used in menopausal women

It can be either combined estrogen progestin therapy (EPT) or estrogen only therapy (ET).

b)Hormonal contraceptives

These can be oral birth control pills, patches injections, implants.

c)Hormones for breast conditions

1 - Selective estrogen receptor modulations (SERMS) - Act like oestrogens in bone but block the effect of oestrogen in breast.

- **Tamoxifen** - Used in both pre and post menopausal women.

It reduces the recurrence risk after early stage breast cancer, treats advanced cancer and prevents breast cancer in high risk healthy women.

- **Raloxifene** - Mainly used in post menopausal women to reduce the risk of invasive breast cancer especially in those at high risk.
- **Toremifene** - It is used in post menopausal women with advanced breast cancer.
- **Fulvestrant** - A SERD (selective estrogen receptor degrader) that blocks and degrades estrogen receptors. It is used for advanced hormones positive breast cancer in post menopausal women who are not responding to other hormone therapies.

2 - Aromatare Inhibitors (AI) There drugs block the enzyme aromatase and hence reduce the amount of oestrogen in the body. These are generally used in post menopausal women.

Drugs are - 1. Anastrozole2. Letrozole 3. Exemestane.

3 - Luteinising Hormone - Releasing Hormone Agonists these drugs like leuprolide, temporarily shut down ovarian function there by reducing oestrogen production in pre menopausal women.

4 -Targeted therapies - some newer drugs like palbociclib, ribociclib and alpelisib are used sometimes with aromatare inhibitors forhormone receptor positive breast cancer.

Risks of Hormonal medications - These vary according to the drug used, duration and patient profile, any preexisting disease, pre or postmenopausal.

Common adverse effects

- Hot Flashes
- Vaginal discharge
- Charge in menstrual pattern.
- Headache, Nausea, constipation.
- Loss of appetite
- Myalgia, arthralgia or fatigue
- Hair loss
- Weight gain
- Mood swings and depression

Less Common but serious side effects

- Deep vein thrombosis and Pulmonary embolism - There is increased risk of thrombosis with SERMS, but not with AIs.
- Endometrial cancer and uterine sarcoma. SERMS increase the risk of endometrial cancer and sarcoma which is due to their estrogen like action. Any abnormal vaginal bleeding is a warning sign.
- Stroke - Tamoxifen increases the chance of stroke esp in postmenopausal women.
- Cataract - Tamoxifen can cause cataracts.
- Bone Problem - Tamoxifen has variable effect on bone health in premenopausal and post menopausal women, causes bone loss in pre but bone strengthening in postmenopausal women.
- Aromatase inhibitors cause bone loss by reducing the oestrogen levels.
- Hypercholesterolemia - Some like elacestrant can increase cholesterol.
- Heart Disease - There is increased risk of heart disease with AIs..

Hormone Replacement therapy (HRT) and breast cancer Risk

- Combined HRT (E+P) There is increased risk of breast cancer with combined therapy, which depends on the duration and age. Discontinuation of HRT reverses the risk.
- Estrogen only HRT (E) - It is usually given to hysterectomiesed women. The risk of breast is lower compared to E+P.
- HRT is usually not given to breast cancer pts with a receptor positive disease.

Benefits of hormonal medications

Pts with receptor positive breast cancer show benefits of hormonal medications as their tumour growth depeneh on hormones (E or P)

For breast cancer treatment and prevention.

- Preventing cancer recurrence: Cancer recurrence can be reduced by hormone therapy in early stage receptor positive breast cancer.
- Neoadjuvant therapy - Large tumour can be shrunken by hormonal therapy before surgery to make it less extensive.

- Controlling advanced cancer : Hormonal therapy can reduce the extent of metastasis and thus improve the life span and quality of life.
- Decreasing risk in High-risk individuals - For women with a strong family history, drugs like tamoxifen or raloxifene can reduce the risk of developing receptor positive cancer.
- Reducing risk in the other Breast Hormonal therapy reduces the risk of developing new cancer in the other breast if someone has had ca breast in one breast

For benign breast disease.

Hormonal medication is generally not reqd for benign breast conditions .Some cases of fibrocystic breast disease may need hormones like, tamoxifen or bromocriptine. The risk of benign breast disease is reduced by anti oestrogen therapy as per some studies.

Factors Affecting risks & Benefits

Hormonal medications should be used after thorough cliscussion with the healthcare people The following points need to be kept in mild

- Type of Breast Disease - whether the disease is benign or malignant, If malignant whether receptor Positive or negative.
- Pre or postmenopausal - This state has an impact on the type of hormone to be used. AI's are preferred in postmenopausal Women.
- Personal factors - Family history, pre existing conditions etc.
- Severity - How virulent is the cancer. How disabling is the benign condition.
- Weighing Pros and cons - This is the most important step in decision making, whether the benefits outweigh the risks or vice versa.

Hormonal Medications for Breast Disease: Risks & Benefits

Medication	Used For	Benefits	Risks / Side Effects
Tamoxifen	Estrogen receptor-positive (ER+) breast cancer; prevention in high-risk women	- Reduces recurrence & mortality in ER+ breast cancer -Prevents contralateral breast cancer	- Hot flashes - Risk of endometrial cancer - Blood clots - Mood changes
Raloxifene	Breast cancer prevention (postmenopausal women)	- Lowers risk of ER+ breast cancer - Also treats osteoporosis	- Hot flashes - Blood clots (less than tamoxifen)

Aromatase Inhibitors (e.g., Letrozole, Anastrozole)	ER+ breast cancer (postmenopausal women)	- More effective than tamoxifen in some postmenopausal cases	- Bone loss - Joint pain - Cardiovascular risk
GnRH Agonists (e.g., Leuprolide)	Premenopausal breast cancer (hormone suppression)	- Suppresses ovarian estrogen - May preserve fertility with chemo	- Menopausal symptoms - Bone thinning - Mood swings
Danazol	Fibrocystic breast disease, severe mastalgia	- Reduces breast pain & nodularity	- Androgenic effects: acne, weight gain, hirsutism - Liver dysfunction
Oral Contraceptives	Cyclical mastalgia, fibrocystic changes	- Regulate hormones - Reduce cyclic breast pain	- Blood clots - Breast tenderness - Slight increase in breast cancer risk
Progesterone (e.g., Medroxyprogesterone)	Mastalgia, hormone imbalance	- Alleviates breast pain - Balances estrogen	- Weight gain - Mood swings - Irregular bleeding

- Summary - Breast health conditions whether benign or malignant can be managed by hormonal medications esp receptor positive breast cancer. It is beneficial in shrinking tumour size, preventing recurrences and managing advanced disease, but has its own set of risks also which may be mild to severe. Treatment plan should be discussed at length with the patient explaining the benefits and risks.

References

- International Journal of Epidemiology Vol 30, Issue 3, June 2001, Pages 423-426 2001.
- Journal of Clinical oncology 41, Pages 857-870 2023.
- Journal of National cancer Institute 91 (21) 1829-1846 (1999)
- International Journal of Endocrinology and metabolism 11c1) 41, 2012
- Yen & Jaffe's Reproductive Endocrinology 2014, Menopause & Aging 318-319 (PTO).
- Berek and Novak's Gynecology 16th Edition (P263-272).

12 Hormonal Medications and Breast Disease: Risks & Benefits.

Author - Dr Asha Jain
Chairperson, Food, Drugs & Medicosurgical Equipment Committee, FOGSI &
President Raipur Menopause Society Raipur CG

1. Introduction

Breast cancer is the most common cancer among women globally, and in India it has now overtaken cervical cancer as the leading cause of cancer-related death in women. A woman's lifetime risk of developing breast cancer is approximately 1 in 8. The disease, however, is not uniform — it has several subtypes with different behaviours, prognoses, and responses to treatment.

Historically, surgery (mastectomy or breast-conserving surgery), radiation therapy, and chemotherapy were the mainstays of treatment. Over the last 25 years, the understanding of the molecular biology of breast cancer has led to more personalised and effective treatment approaches. Newer agents — including targeted therapies, antibody–drug conjugates (ADCs), immunotherapy, and advanced hormonal therapies — are now available. These have improved survival rates and, in many cases, reduced side effects compared to older treatments.

For gynaecologists, especially those involved in women's health across the lifespan, being aware of these evolving drug options is important because:

- Many patients first present to their gynaecologist with breast symptoms.
- Survivors of breast cancer often continue their routine care with their gynaecologist.
- Knowledge of current treatments enables better counselling, surveillance, and coordination with oncology teams.

2. Understanding the Molecular Subtypes

Breast cancers are classified based on the presence or absence of certain receptors on the tumour cell surface:

1. **Hormone Receptor (HR)–positive:**
   - Oestrogen receptor (ER) and/or progesterone receptor (PR) present.
   - Makes up ~70% of breast cancers.
   - Usually responds well to hormone-blocking (endocrine) therapy.
2. **HER2-positive:**
   - Overexpression of the HER2 (human epidermal growth factor receptor 2) protein.
   - Accounts for ~15–20% of cases.
   - More aggressive but very responsive to HER2-targeted drugs.
3. **Triple-Negative Breast Cancer (TNBC):**
   - Lacks ER, PR, and HER2.
   - Accounts for ~10–15% of cases.
   - More aggressive, fewer treatment options, but newer drugs are changing this.

4. HER2-low:

- Not enough HER2 for classical HER2-positive diagnosis, but still detectable at low levels.
- Recognised as a separate group because some new drugs work in these tumours.

3. Principles of Breast Cancer Pharmacotherapy

The choice of drug depends on:

- **Subtype** (HR, HER2, TNBC).
- **Stage** (early vs metastatic).
- **Patient factors** (age, menopausal status, comorbidities).
- **Molecular profile** (genetic mutations like BRCA, PIK3CA, ESR1).
- **Treatment goals** (curative vs control in metastatic setting).

Traditionally, chemotherapy affected all rapidly dividing cells, leading to widespread side effects. Newer targeted therapies aim to selectively attack cancer cells, sparing normal tissues, which improves tolerability and efficacy.

4. Advances in HER2-Positive Breast Cancer

HER2-positive cancers once had a poor prognosis, but this changed with the advent of **trastuzumab (Herceptin)** in the late 1990s.

4.1 Monoclonal Antibodies

- **Trastuzumab**: Attaches to HER2 receptors, blocking growth signals and attracting immune cells to destroy the cancer cell.
- **Pertuzumab**: Works at a different site on the HER2 receptor; combining with trastuzumab provides a "dual blockade" for greater efficacy.
- **Margetuximab**: A newer antibody engineered to better activate immune attack.

4.2 Tyrosine Kinase Inhibitors (TKIs)

- Small molecules like **lapatinib, neratinib, tucatinib** enter the cell and block the HER2 signal from the inside.
- Tucatinib is particularly useful in controlling brain metastases.

4.3 Antibody–Drug Conjugates (ADCs)

- These combine an antibody that targets HER2 with a potent chemotherapy drug, delivering the drug directly to the cancer cell:
  - **T-DM1 (trastuzumab emtansine)**: Used after trastuzumab if cancer recurs or persists.
  - **Trastuzumab deruxtecan (T-DXd)**: More potent than T-DM1 and effective even in HER2-low tumours.

5. Advances in Hormone Receptor–Positive Breast Cancer

These cancers depend on oestrogen and/or progesterone for growth.

5.1 Endocrine Therapies

- **Selective Oestrogen Receptor Modulators (SERMs)**: Tamoxifen blocks the oestrogen receptor in breast tissue.
- **Aromatase Inhibitors (AIs)**: Letrozole, anastrozole, exemestane reduce oestrogen production in postmenopausal women.
- **Selective Oestrogen Receptor Degraders (SERDs)**: Fulvestrant and newer oral agents like elacestrant destroy the oestrogen receptor.

5.2 Overcoming Endocrine Resistance

When cancers stop responding to hormones alone:

- **CDK4/6 inhibitors**: Palbociclib, ribociclib, abemaciclib slow down cancer cell division.
- **PI3K inhibitors**: Alpelisib for cancers with PIK3CA mutation.
- **AKT inhibitors**: Capivasertib under evaluation for resistant disease.
- **mTOR inhibitors**: Everolimus can restore sensitivity to hormone therapy.

6. Triple-Negative Breast Cancer (TNBC)

TNBC is aggressive and lacks hormone or HER2 targets, but new treatments are emerging.

6.1 Immunotherapy

- **Pembrolizumab** (PD-1 inhibitor) stimulates the immune system to attack cancer, used in high-risk early TNBC and selected metastatic cases.

6.2 ADCs

- Sacituzumab govitecan: Targets TROP-2 and delivers SN-38 (a chemotherapy drug) directly to the cancer cell.

6.3 PARP Inhibitors

- Olaparib, talazoparib are effective in BRCA mutation–positive TNBC.

7. Metastatic Breast Cancer (MBC)

Metastatic disease means cancer has spread beyond the breast and regional lymph nodes. Goals of therapy shift to:

- Prolong life.
- Control symptoms.
- Maintain quality of life.

Current approach:

- Use most effective drug class first for that subtype.
- Sequence treatments to delay resistance.
- Use CNS-penetrant drugs when brain metastases are present.
- Integrate palliative care early.

Emerging concepts in MBC include:

- **Liquid biopsies** to detect mutations and adapt treatment early.
- **Adaptive clinical trials** to quickly bring promising drugs into use.

8. Personalised Medicine

Personalisation means matching the right drug to the right patient:

- **Genetic testing**: BRCA, PALB2, PIK3CA, ESR1 mutations guide targeted drug use.
- **HER2-low testing**: Identifies candidates for T-DXd.
- **ctDNA monitoring**: Detects relapse earlier than imaging.

Artificial intelligence and molecular profiling will likely further refine these decisions in coming years.

9. Managing Side Effects

Even targeted drugs have side effects. Awareness helps early recognition and management:

Drug Class	Common Side Effects	Mitigation Strategies
HER2 antibodies	Heart weakness	Baseline echo, monitor EF, cardiology input
TKIs	Diarrhoea, rash	Early antidiarrhoeals, skin care
ADCs	Low blood counts, lung inflammation	CBC monitoring, prompt steroids for lung symptoms
PI3K inhibitors	High blood sugar	HbA1c monitoring, diet, diabetes medication
CDK4/6 inhibitors	Neutropenia	CBC monitoring, dose adjustment
Immunotherapy	Autoimmune effects	Early detection, steroids if needed

Patient education is critical — patients should know which symptoms require urgent reporting.

10. Recent Drug Approvals and Pipeline

2023–2024 approvals:

- Olaparib for BRCA-mutated primary breast cancer.
- Talazoparib for HER2– MBC with BRCA mutation.
- Elacestrant for ESR1-mutated ER+/HER2– disease.
- Trastuzumab deruxtecan for HER2-low secondary breast cancer.

In pipeline:

- Inavolisib (next-gen PI3K inhibitor).
- Patritumab deruxtecan (HER3-targeted ADC).
- Sacituzumab govitecan in earlier lines.

11. Overcoming Resistance

Cancers adapt to survive drug therapy:

- **Mutation of drug targets** (e.g., ESR1 mutations causing hormone resistance).
- **Activation of alternate pathways** (PI3K/AKT, HER3).
- **Bypass signalling** (using different receptors).

Strategies include combining drugs with different mechanisms, sequencing treatments, and using biomarker monitoring to detect resistance early.

12. What Gynaecologists Should Take Away

- **Be familiar with subtypes** — they dictate treatment.
- **Recognise the names of key drugs** to understand what your patient is receiving.
- **Monitor for and manage common side effects** — especially cardiac and metabolic ones.
- **Coordinate care** with oncologists and encourage adherence to follow-up.
- **Support survivorship** — including menopausal symptoms, bone health, and psychosocial support.

13. Conclusion

Breast cancer pharmacotherapy is in a rapid phase of evolution, shifting from one-size-fits-all chemotherapy to biomarker-driven, personalised medicine. For the general gynaecologist, understanding these advances is essential for informed counselling, survivorship care, and timely referral. As new agents such as ADCs, PARP inhibitors, oral SERDs, and immunotherapies expand treatment possibilities, the focus remains on improving survival while minimising toxicity and preserving quality of life.

References

1. Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23(4):2288.
2. Masoud V, Pagès G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120-34.
3. Bartsch R. Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease. Memo. 2024;17:204–9.
4. Breast Cancer Now. New drugs approved in 2023 and what's coming up in 2024. 2024.
5. Breast Cancer Now. New drugs approved in 2024 and what's coming up in 2025. 2025.
6. National Cancer Institute. Advances in Breast Cancer Research. 2024.
7. Susan G. Komen. Emerging areas in metastatic breast cancer treatment. 2023.

13 Topical Agents For Breast Disorders

Author - DR. NEETHA GEORGE
MS DGO FMAS FICOG
Diploma in Lap, Hysteroscopy, Urogynaec (Kiel),
Assoc.Prof in OBG ,JMMC ,Thrissur ,Kerala

For breast pain (mastalgia)

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are a first-line treatment for both cyclical and non-cyclical breast pain.

Diclofenac gel: A topical NSAID that has been shown to effectively reduce pain in many women with mastalgia. It is available by prescription and is generally considered safe and well-tolerated, with minimal systemic absorption.

Ibuprofen gel: Topical ibuprofen has also been used for breast pain, though some studies suggest that topical diclofenac may be more effective.

For cancer prevention and treatment

Topical agents are being investigated for breast cancer, leveraging the benefit of local application to reduce systemic toxicity.

Tamoxifen gel: A gel form of the selective estrogen receptor modulator (SERM), 4-hydroxytamoxifen (4-OHT), is under investigation for breast cancer prevention and treating ductal carcinoma in situ (DCIS). Clinical trials show it can achieve drug levels in the breast tissue similar to oral tamoxifen but with significantly lower plasma levels and fewer side effects.

Miltefosine: This topical cytostatic agent has shown effectiveness as a local treatment for cutaneous (skin) metastases from breast carcinoma.

For fibrocystic breast changes

Some topical and supplemental therapies are used for symptomatic relief of fibrocystic breasts, though their effectiveness can vary.

Progesterone gel: In small studies, topical progesterone gel has been shown to reduce breast pain and the size and number of cysts associated with fibrocystic changes. However, more research is needed to confirm its safety and efficacy.

Topical danazol: The oral form of danazol is FDA-approved for treating fibrocystic breasts, but it carries a risk of severe side effects. Topical forms are being studied to determine if they offer similar benefits with fewer systemic side effects.

For radiation dermatitis

During and after radiation therapy for breast cancer, topical agents help manage treatment-related skin reactions. Topical corticosteroids (e.g., betamethasone): When used daily, topical betamethasone has been shown to reduce the severity of acute radio dermatitis in patients receiving radiation therapy for breast cancer.

Moisturizers and emollients (e.g., Aquaphor, Miaderm): These are frequently used to soothe irritated skin from radiation. While both are commonly recommended, it is not clear whether one is more effective than the other.

For breastfeeding-related issues

Nursing mothers often use topical creams to treat sore, dry, or cracked nipples.

Lanolin cream: This 100% natural, hypoallergenic, and non-toxic cream is used to soothe and protect sore and cracked nipples. It is safe for the baby and does not need to be removed before breastfeeding.

Herbal and natural butters: Products like organic nipple cream made with ingredients like shea butter are also popular choices for nursing mothers

FUTURE TRIALS

Trials revealed interesting characteristics of medications and their capabilities when applied topically or when in an altered delivery form.

Using 1% oleic acid as a vehicle in a formulation of endoxifen (a tamoxifen metabolite) significantly improved its penetration and tissue absorption in an in-vitro evaluation in human epidermis.

Similarly, an emu oil-enhanced transfersomal (artificial vesicle) formulation showed equivalent efficacy in reducing tumor volume and necrosis when compared to oral tamoxifen in mouse models of breast cancer. The transfersomal formulation also resulted in lower plasma concentrations than oral tamoxifen, reducing systemic adverse effects.

An in vivo test of 5-fluorouracil applied topically to rat nipples showed a higher concentration in breast tissue than with intravenous or transdermal application. This shows the potential for the nipple as localized administration to the breast.

Furthermore, using iontophoresis increased drug delivery of miproxifen phosphate directly to the lactation ducts of rat epidermis and resulted in greater drug availability at a lower dosage in the mammary tissue. Iontophoresis is a novel drug delivery system that uses electrical stimulation, applying a negatively or positively charged current to skin treated with a medicated solution with the same polarity. These results show the potential for this system for targeted therapy.

REFERENCES

1. Breast cancer. World Health Organization. March 13, 2024. Accessed January 31, 2025. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2. Thilagam NBS, Karthik V, Gnanasambandan R et al. A comprehensive review on current knowledge and future potential of topical therapies in breast cancer treatment. Eur J Breast Health. 2025;21(1):9-15. doi:10.4274/ejbh.galenos.2024.2024-9-9

14 Drugs Affecting Lactation

Author- Dr Prabhdeep Kaur
DGO DNB CIMP
CONSULTANT OBGY
JLNH AND RC BHILAI CG

Breastfeeding is most effective when natural processes are supported and unnecessary medications are avoided. Still, in everyday obstetric care, various medications—whether prescribed, over-the-counter, or herbal—can influence lactation, sometimes helping and sometimes hindering milk production. This section combines recommendations from the ABM Clinical Protocol on Galactagogues (2018), the updated NICE breastfeeding guidance (now in NG194), and FOGSI's 2020 guidelines, offering a practical reference for counseling, prescribing, and managing lactation-related concerns in clinical practice.

1. Foundational Principles: Optimize Before Medicating

All major guidelines agree: before considering medication to boost milk supply, it's essential to address feeding mechanics and milk removal. This includes frequent, effective, and comfortable breastfeeding or pumping, skin-to-skin contact, and skilled early support. The ABM protocol clearly states that galactagogues should never be the first option and ought to be reserved only after all modifiable causes of low supply—such as poor latch, infrequent feeds, maternal illness, retained placenta, or thyroid issues—have been addressed. If a medication is considered, it should be with shared decision-making, clear goals, and close monitoring.

NICE postnatal care guidance also highlights the importance of timely, high-quality support and appropriate, safe medicine use during lactation, as well as directing families to trustworthy resources and avoiding unnecessary pharmacological suppression of lactation.

FOGSI's recommendations reinforce public health priorities: start breastfeeding early, avoid prelacteal feeds, keep babies with mothers (rooming-in), and protect exclusive breastfeeding—all of which reduce the need for later medical interventions for low milk supply.

2. Medications That Reduce Milk Production

A. Dopaminergic Agents (Prolactin Suppressors)

Dopamine agonists like bromocriptine and cabergoline suppress prolactin and are effective for stopping lactation. These medications should only be used when lactation suppression is medically necessary (e.g., after perinatal loss or specific infections). Bromocriptine is not recommended for routine use due to risks like hypertension and neurological or cardiovascular events; regulatory bodies recommend careful selection and monitoring of blood pressure.

Cabergoline, with a simpler dosing schedule and better safety profile, is increasingly preferred for lactation suppression. For example, a single 1 mg oral dose immediately postpartum may be used for prevention, but any breast stimulation can counteract the suppression. Note that protocols may differ and cabergoline use may be off-label.

B. Oestrogens and Combined Hormonal Contraceptives (CHCs)

Oestrogens can interfere with the onset of mature milk production, so combined hormonal contraceptives should be avoided in the immediate postpartum period for breastfeeding parents. Use progestin-only methods initially and wait until lactation is well established before considering CHCs, according to consensus among major guidelines and FOGSI's family planning recommendations.

C. Sympathomimetics and "Drying" OTC Medications

Pseudoephedrine can cause a rapid reduction in milk production—a single 60 mg dose has been shown to reduce output by about 24%. Non-systemic options like saline or topical decongestants (used sparingly) should be chosen instead. Advise parents that repeated doses may further decrease supply.

D. Other Potential Supply Reducers

Drugs like ergot derivatives (e.g., methylergonovine), high-dose diuretics, and heavy or chronic alcohol use may also lower milk supply, often by impairing oxytocin-driven milk letdown. Prefer alternatives that do not affect lactation and address underlying health issues using non-pharmacological approaches first. When a medicine affecting supply is unavoidable, more frequent milk removal can help mitigate supply loss.

3. Drugs Proposed to Increase Milk Production (Galactagogues)

A. Guidance from the Academy of Breast-feeding Medicine

The ABM Clinical Protocol #9 finds that evidence for pharmaceutical galactagogues is inconsistent, and benefits are modest at best. Drug therapy to increase milk production should only follow correction of all modifiable causes, be for a limited time, and always involve clear communication about risks, potential benefits, and the uncertainty of effectiveness. No galactagogue is recommended as standard care.

B. Domperidone

Effectiveness: Randomized trials, mainly in mothers of preterm infants pumping for the NICU, have shown moderate increases in milk production with domperidone over 7–14 days, but results vary, and the benefit is most consistent in this specific group.

Safety & Regulation: Due to cardiac risks (QT prolongation, arrhythmias), there are strict regulatory warnings. The FDA does not allow domperidone for milk production except through investigational use; in the UK, its use is restricted and carries cardiac risk warnings. Use outside of specialist guidance is not recommended. If considered, always use the lowest effective dose for the shortest practical period, carefully screen for cardiac risk factors and drug interactions, and discontinue if there is no response in about 1–2 weeks.

C. Metoclopramide

Effectiveness: Recent systematic reviews show that metoclopramide does not consistently increase milk production.

Safety: Risks include maternal depression and neurological effects (e.g., movement disorders), leading to significant restrictions on its use. If tried, it should be for a very limited time with careful mental-health monitoring.

D. Herbal Galactagogues

The ABM notes the lack of high-quality evidence for herbal options like fenugreek, shatavari, or milk thistle. Potency, quality, and safety vary widely; contamination, allergens, and drug interactions are real risks. If a family chooses to try a herbal galactagogue, only one new substance should be trialed at a time, with careful documentation of milk volumes, and discontinued after 1–2 weeks if there is no clear benefit—while continuing to support proper feeding technique and frequent milk removal.

4. NICE & FOGSI: Translating Guidance into Practice

NICE (2020/NG194) emphasizes proactive support, prompt recognition and management of breastfeeding challenges, and safe prescribing. The guidance also covers the use of medications to suppress lactation when clinically necessary and encourages clear care planning. Locally, this translates to early expert help with latch and pain management, routine medicine review for lactating women, and providing written aftercare about safe medicine use.

FOGSI (2020) stresses BFHI-style policies: early breastfeeding initiation, exclusive breastfeeding, avoidance of prelacteal feeds, and guidance on contraception that does not hinder early lactation (favoring progestin-only methods and postponing CHCs until supply is robust). Align discharge counseling on contraception with these principles.

References (Guideline-Anchored)

- ABM Clinical Protocol #9: Use of Galactogogues in Initiating or Augmenting Maternal Milk Production (2018)
- NICE Breastfeeding Guidance (2020 content now within NG194: Postnatal care)
- FOGSI Recommendations/Policy Statement (2020)

----------XXXXX----------

15

Breast Prosthesis And Reconstructive Equipments

Author :Dr Sugandha Goel
Infertility Specialist and Laparoscopic Surgeon Director of Kamla Nagar Hospital (100 bedded DNB OBS GYNAC AFFILIATED, NABH & NABL Accredited Hospital) Jodhpur Rajasthan

Co- Author :Dr Aakanksha Tiwari MBBS, DNB 1st year Kamla Nagar Hospital, Jodhpur Rajasthan

Introduction

Mastectomy remains a common treatment for breast cancer. After mastectomy, the loss of breast tissue has not only physical but also psychological and social implications for the patient. Reconstruction—whether external or surgical—is pivotal to patient quality of life. External breast prostheses provide a simple and non-invasive method to restore body contour and improve confidence. For patients opting for surgical management, reconstruction can be achieved using implants, tissue expanders, autologous flaps, or newer techniques incorporating acellular dermal matrices and bioengineered scaffolds. While prosthetics are cost-effective and widely available, surgical reconstruction offers more permanent results but carries risks such as infection, implant rupture, and donor site morbidity. Recent advances include the use of 3D printing, fat grafting, and oncoplastic techniques, which aim to provide more natural aesthetic outcomes.

1. External Breast Prosthetics - A non-surgical, artificial breast form worn externally to replicate the shape and feel of a natural breast. Post mastectomy, the loss of breast weight, especially in unilateral cases, may lead to compensatory posture, resulting in shoulder asymmetry, scapular tilt, and chronic pain in the neck and back. A weighted silicone EBP helps restore this balance. EBPs can provide protection for the surgical site once it has healed, shielding the sensitive area from external friction and injury. For many, an external prosthesis can aid in the emotional healing process by restoring a sense of normalcy and body image after surgery.

1.1 Types and Materials

External breast prostheses include full, partial, shell, stick-on, and custom-made designs. Materials range from silicone gel to lightweight foam and fabric; adhesive-backed and pocketed variations accommodate different use scenarios

1.2 Patient Experience and Satisfaction

Most long-term users report high satisfaction: 83% of women wore prostheses almost daily, especially as they passed five years post-mastectomy (satisfaction: 90% vs. 67%)(1) Qualitative studies reveal that although prostheses aid in body image restitution, challenges include weight, heat, discomfort, and lack of information or access .

1.3 Accessibility in Low-Resource Settings

In India, only 40% used any type of prosthesis; many rely on home-made versions like cloth or cotton (44%) due to cost and limited awareness (2). A study from Brazil introduced a low-cost, lightweight, washable model, which was preferred—sometimes even over silicone products—highlighting the potential of affordable innovation (3)

1.4 Innovations

Architected materials using 3D printing can replicate the density, thermal conductivity, and mechanical behavior of natural breast tissue, addressing concerns like weight, heat, and personalization.

Mobile 3D scanning allows for creation of custom-made prostheses and enables monitoring of tissue regeneration and prosthesis integration remotely.

Implant-Based Reconstruction

Devices include saline- or silicone-filled implants, available in round or anatomic forms, with smooth or textured surfaces. The reconstruction may be performed in a single stage (direct-to-implant) or as a two-stage procedure using tissue expanders followed by permanent implants.

Complications

Complications include infection, seroma, implant malposition, capsular contracture, rupture, and, rarely, breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL). Patients requiring adjuvant radiotherapy face higher complication and failure rates, favouring autologous alternatives.

Role of Acellular Dermal Matrices (ADM)

The incorporation of ADMs has revolutionized implant-based reconstruction, these provide soft tissue coverage, facilitate tissue incorporation and revascularization, and improve cosmetic outcomes by enhancing breast contour and stability. ADMs also help prevent complications like capsular contracture, implant malposition, and wrinkling, making them a cornerstone of modern implant-based breast reconstruction.

Tissue Expanders

Tissue expanders are temporary devices designed to gradually stretch mastectomy skin flaps to create a pocket for permanent implants. They are equipped with self-sealing ports through which saline is serially injected over weeks. Expanders play a crucial role in staged reconstructions, particularly in patients with insufficient soft tissue.

Although generally safe, complications such as infection, extrusion, and rupture occur in up to 20% of cases (4). Newer expanders incorporate remote-controlled magnetic or CO_2 release mechanisms, reducing clinic visits and improving patient comfort.

Autologous Reconstruction

Flap Options

Autologous reconstruction remains the gold standard for many patients due to superior aesthetic outcomes, durability, and natural feel. Common donor sites include:

- **TRAM flap** (transverse rectus abdominis myocutaneous) – skin and fat from the abdomen along with a segment of the rectus abdominis muscle is used. It is robust technique but associated with abdominal wall morbidity.

- **DIEP flap (deep inferior epigastric perforator) –** this technique isolates the blood vessels (perforators) from the surrounding rectus muscle, harvesting only the skin, fat, and the feeding vessels. The rectus muscle and nerves are left intact, preserving the abdominal wall's strength. It is muscle-sparing so reduced donor morbidity but is technically demanding.

- **Latissimus dorsi flap –** It is often used for smaller reconstructions, to correct lumpectomy defects, or in conjunction with an implant to provide more volume and coverage. It has reliable vascularity and is a reliable option for patients who may not be candidates for abdominal flaps. The use of back muscle can cause some weakness, though this is rare. The donor site on the back can also result in seroma (fluid accumulation).

- **Gluteal (SGAP, IGAP), thigh (TUG, PAP), and lumbar flaps –** options for patients lacking adequate abdominal tissue.

Advances in Technique

Modern microsurgical approaches, including perforator flaps and supermicrosurgery, have reduced donor morbidity and improved outcomes. Neurotization of flaps offers the possibility of restoring sensation. Robotic-assisted harvest is under exploration.

Limitations

Challenges include longer operative times, need for microsurgical expertise, donor site morbidity, and higher perioperative risk in comorbid patients.

Hybrid Reconstruction

Hybrid reconstruction combines autologous flaps with implants to augment volume and contour. This is particularly advantageous in patients with limited donor tissue or in those undergoing post-mastectomy radiotherapy, where autologous tissue protects the implant. Recent evidence demonstrates improved aesthetic outcomes and lower implant loss compared with implant-only reconstructions (5).

Future Directions

Innovations shaping the future include:

- **3D printing and custom implants/prostheses** for patient-specific reconstruction.
- **Tissue engineering and bioengineered scaffolds** for autologous-like outcomes without donor morbidity.
- **Smart prostheses** with thermoregulation and sensory feedback.
- **Robotic microsurgery** for enhanced precision and reduced invasiveness.

Continued emphasis on patient-reported outcomes and long-term safety studies will guide future practice.

Conclusion

Breast prosthetics and reconstruction equipment provide a wide spectrum of options, from external prostheses to advanced autologous reconstructions. While prostheses remain vital for patients declining or unsuitable for surgery, implant-based and autologous reconstructions dominate surgical practice. Hybrid approaches, ADM-supported implants, and microsurgical refinements represent ongoing innovation. Personalized reconstruction, integrating oncological, functional, and psychosocial factors, remains the cornerstone of care.

References (ICMJE style)

- 1.Glaus A, Carlson G. Long-Term Role of External Breast Prostheses After Total Mastectomy. Breast J. 2009 Jul-Aug;15(4):362-368.
- 2.Ramu D, Ramesh RS, Manjunath S, Shivakumar, Goel V, Hemnath GN, Alexander A.Indian J Surg Oncol. 2015 Dec;6(4):374-7. doi: 10.1007/s13193-015-0456-2. Epub 2015 Oct 18.PMID: 27065664
- 3.Alvarenga M, de Paula-Filho E, Fernandes S, et al. External breast prostheses after mastectomy: production and selection of a low-cost, functional model to be performed in developing countries [published online ahead of print, 2024 Aug 7]. Front Oncol. 2024;14:1440109. doi:10.3389/fonc.2024.1440109.
- 4.Spear SL, Parikh PM, Reisin E, Menon N. Acellular dermis-assisted breast reconstruction. Aesthet Surg J. 2008;28(5):585-93.
- 5.ahabedian MY. Implant-based breast reconstruction and radiation: short-term versus long-term outcomes. Plast Reconstr Surg. 2009;123(3):1409-19.

----------XXXXX----------

16 Medico-Legal Aspects of Breast Imaging and Intervention

Author :Dr Ragweshwar Jyoti Mahajan
Assistant Professor, KNSHM&C, IGMC,
Shimla (Himachal Pradesh)

Introduction

Breast imaging and intervention play an important role in the early detection, diagnosis and management of breast diseases and cancer. While these medical practices offer immense benefits, they are also having complex medico-legal challenges. Healthcare professionals involved in breast imaging—radiologists, radiographers, sonographers, breast care nurses and surgeons who operate within a highly scrutinized environment where diagnostic accuracy, timely intervention, effective communication and meticulous documentation are very important. Failures in any of these areas can lead to significant patient harm, professional liability and legal repercussions.

This chapter aims to provide a comprehensive overview of the legal and ethical obligations of healthcare providers, common areas of litigation, the importance of informed consent, the intricacies of duty of care, the implications of diagnostic errors and the critical role of robust documentation and communication in reducing risks. Understanding these aspects is not merely a legal formality but a fundamental component of delivering high-quality and patient-centred care while safeguarding both the patient's well-being and the professional's integrity.

Duty of Care and Standard of Care

The cornerstone of medico-legal responsibility is the "duty of care." Every healthcare professional owes a duty of care to their patients, meaning they must act with reasonable skill and care in providing medical services. In the context of breast imaging and intervention, this duty encompasses:

1. **Competence:** Possessing the necessary knowledge, skills and experience to perform breast imaging procedures (mammography, ultrasound, MRI) and interventions (biopsies, localizations) accurately and safely.
2. **Diligence:** Performing examinations and interpretations thoroughly, not missing significant findings due to haste or oversight.
3. **Timeliness:** Ensuring that imaging studies are performed and reported in a timely manner, especially when there is a suspicion of malignancy, as delays can impact prognosis.
4. **Appropriate Referral**: Referring patients for further imaging, biopsy or specialist consultation when indicated by findings.

The "standard of care" defines the level of care that a reasonably prudent healthcare professional would provide under similar circumstances. It is not a standard of perfection but rather what is generally accepted as good medical practice within the specialty. In litigation, the standard of care is often established through expert testimony, drawing upon professional guidelines, consensus statements, peer-reviewed literature and common practice.

For breast imaging, this includes adherence to guidelines from bodies such as the American College of Radiology (ACR), European Society of Breast Imaging (EUSOBI) and national screening programs. Deviations from the accepted standard of care that result in patient harm can form the basis of a negligence claim.

Informed Consent in Breast Imaging and Intervention

Informed consent is a fundamental ethical and legal requirement before any medical procedure. It ensures patient autonomy and protects healthcare providers from claims of negligence. For breast imaging and intervention, the consent process must consist of several key elements:

1.**Disclosure of Information**: Patients must be provided with sufficient information about the proposed procedure. This includes:

- The nature and purpose of the procedure (e.g., diagnostic mammogram, ultrasound-guided biopsy).
- The potential benefits (e.g., early detection of cancer, accurate diagnosis).
- The material risks (common and serious complications such as pain, bruising, infection, bleeding, scarring, false positives/negatives, radiation exposure from mammography).
- Alternative procedures or treatments (e.g., observation, different imaging modalities, open biopsy).
- The consequences of refusing the procedure.

2. **Patient Understanding**: The information must be presented in a clear and understandable language, avoiding medical terminologies. The healthcare professional must verify that the patient comprehends the information, allowing them to ask questions and clarifying any doubts. Special consideration should be given to patients with language barriers, cognitive impairments or low health literacy.

3. **Voluntariness:** Consent must be given freely, without coercion or undue influence.

4. **Capacity**: The patient must have the mental capacity to make an informed decision. This means they must understand the information, appreciate the consequences of their decision and be able to communicate their choice. For patients lacking capacity, consent may need to be obtained from a legally authorized decision-maker.

Specific considerations for breast imaging and intervention include:

- **Mammography**: While generally considered a low-risk procedure, patients should be informed about radiation exposure (though minimal), the possibility of discomfort during compression and the potential for false positives (leading to anxiety and furtheprocedures) or false negatives (missing a cancer).
- **Biopsies (Core Needle, Vacuum-Assisted, Excisional)**: Detailed discussion of risks like bleeding, infection, hematoma formation, pain, scarring and the possibility of non-diagnostic or discordant results requiring further intervention. The patient should also understand the implications of the biopsy result (benign, high-risk, malignant) and the subsequent management plan.

- **Pre-operative Localization**: Patients undergoing wire or radioactive seed localization should be informed about the procedure's purpose, the discomfort and the risks associated with the localization method.

Documentation of informed consent is crucial. A signed consent form along with detailed notes in the patient's medical record outlining the discussion, the information provided and the patient's understanding serves as legal proof that the process was followed.

Diagnostic Errors and Misdiagnosis

Diagnostic errors are a leading cause of medical malpractice claims in breast imaging. These errors can manifest in several ways:

1. **Failure to Diagnose**: This is the most common and often most devastating error. It includes:
    - **Perceptual Errors**: The radiologist fails to identify an abnormality that is visible on the imaging study (e.g., missing a subtle mass or calcifications). This can be due to fatigue, distraction or lack of experience.
    - **Cognitive Errors**: The radiologist sees an abnormality but misinterprets its significance, leading to an incorrect diagnosis or an inappropriate recommendation (e.g., interpreting a malignant lesion as benign, or recommending routine follow-up instead of biopsy).
    - **Technical Errors**: Poor image quality due to improper technique (e.g., inadequate compression in mammography, incorrect probe placement in ultrasound) that obscures pathology.
    - **Systemic Errors**: Failures in the healthcare system, such as lost images, incorrect patient identification, or delayed reporting.

2. **Delayed Diagnosis**: While the cancer may eventually be diagnosed, a significant delay in diagnosis (e.g., due to a missed finding on a previous scan or a delay in recommending further investigation) can lead to disease progression, requiring more aggressive treatment and potentially worsening prognosis.

3. Misdiagnosis (False Positive): Interpreting a benign finding as suspicious for malignancy, leading to unnecessary biopsies, anxiety and potential complications from invasive procedures. While less common in litigation than missed cancers, false positives can still lead to claims for emotional distress or complications from the unnecessary procedure.

Preventing diagnostic errors requires a multi-pronged approach:

- **Continuous Education and Training**: Radiologists and other imaging professionals must engage in ongoing learning to stay up to date to new imaging techniques, diagnostic criteria and best practices.
- **Quality Assurance Programs:** Regular peer review, audit of diagnostic accuracy and correlation of imaging findings with pathology results are essential for identifying areas for improvement.
- **Use of Technology:** CAD (Computer-Aided Detection) systems can assist in highlighting suspicious areas, though they are not a substitute for human interpretation. AI tools are also emerging.
- **Second Opinions:** Encouraging second reads for complex or equivocal cases, especially in high-volume screening programs.
- **Time and Resources:** Ensuring radiologists have adequate time and a conducive environment to interpret studies without undue pressure or distraction.

When a diagnostic error occurs, the legal focus will be on whether the error fell below the accepted standard of care and whether it directly caused or contributed to the patient's harm.

Communication and Documentation

Effective communication and meticulous documentation are critical defensive strategies against medico-legal claims.

Communication:

1. Radiologist to Referring Physician: Clear, concise and timely communication of imaging findings, particularly critical or urgent results. This includes using structured reporting (e.g., BI-RADS lexicon) and direct communication for highly suspicious findings. Recommendations for further management must be explicit.

2. **Radiologist/Team to Patient**: While often mediated by the referring physician, direct communication with the patient may be necessary, especially during interventions or when explaining complex findings. Patients should be informed about their results in an empathetic and understandable manner.

3. **Interdisciplinary Communication**: Seamless communication among all members of the breast care team (radiologists, surgeons, oncologists, pathologists, nurses) is vital for coordinated care and avoiding miscommunication that can lead to errors. Regular multidisciplinary team (MDT) meetings are essential for discussing complex cases and formulating management plans.

Documentation:

"If it's not documented, it didn't happen." This adage holds immense weight in medico-legal contexts. Comprehensive documentation serves multiple purposes:

1. **Legal Record:** It provides a factual account of the patient's care, serving as evidence in legal proceedings.
2. **Continuity of Care:** Ensures that all healthcare providers involved in the patient's care have access to complete and accurate information.
3. **Quality Improvement:** Allows for audit and review of practices.

Key elements of documentation in breast imaging and intervention include:

- **Clinical History**: Detailed patient history, including symptoms, risk factors, previous breast issues and family history.
- **Imaging Reports**: Comprehensive reports for each study, including:
    - Date and time of examination.
    - Patient demographics.
    - Clinical indication.
    - Technical details (e.g., views obtained, contrast administered).
    - Detailed description of findings (location, size, morphology of lesions, calcifications, architectural distortion, lymph nodes).

- BI-RADS assessment category.
- Clear recommendations for further management (e.g., follow-up, biopsy, surgical consultation).
- Radiologist's signature and date.

- **Procedure Notes (for Interventions):**
  - Indication for the procedure.
  - Informed consent documentation (who obtained it, what was discussed, patient's understanding).
  - Type of anaesthesia.
  - Detailed description of the procedure (e.g., needle gauge, number of passes, amount of tissue removed, use of clips).
  - Complications encountered.
  - Post-procedure instructions given to the patient.
  - Specimen handling and submission details.

- **Communication Records**: Documenting all significant communications with the patient, referring physician and other team members, including date, time and content of discussion.
- **Follow-up Tracking**: Systems to ensure that patients receive appropriate follow-up for suspicious or indeterminate findings.

Poor or incomplete documentation can significantly weaken a healthcare professional's defence in a negligence claim even if the care provided was appropriate.

Specific Medico-Legal Challenges

1. Screening vs. Diagnostic Mammography

The medico-legal implications differ between screening and diagnostic mammography.

- **Screening Mammography**: A population-based program aimed at detecting early, asymptomatic cancers. The standard of care acknowledges that some cancers may be missed (interval cancers) due to their subtle nature or rapid growth. However, a missed cancer on a screening mammogram that was retrospectively visible (perceptual error) or misinterpreted (cognitive error) can lead to a claim.
- **Diagnostic Mammography**: Performed due to symptoms (e.g., lump, pain, nipple discharge) or an abnormal screening result. The standard of care is generally higher, requiring more thorough evaluation and often additional views or modalities (ultrasound, MRI) to fully characterize findings. Missed cancers in this setting are often viewed more critically.

2. Management of BI-RADS 3 and BI-RADS 4 Lesions

- **BI-RADS 3 (Probably Benign)**: Lesions with a very high likelihood of being benign (<2% chance of malignancy) for which short-interval follow-up (e.g., 6 months) is recommended instead of immediate biopsy. If a BI-RADS 3 lesion turns out to be malignant, the defence will hinge on whether the initial assessment was reasonable based on the imaging characteristics and whether the follow-up was appropriately managed. Meticulous documentation of the discussion with the patient about the BI-RADS 3 assessment and the need for follow-up is crucial.

- **BI-RADS 4 (Suspicious Abnormality)**: Lesions with a definite suspicion of malignancy (2-94% chance) requiring biopsy. Failure to recommend or perform a timely biopsy for a BI-RADS 4 lesion that proves to be cancerous is a significant medico-legal risk.

- **3. Incidental Findings**

Breast imaging studies, particularly MRI, may reveal incidental findings in other areas (e.g., thyroid nodules, lung nodules). While the primary focus is the breast, there is a duty to communicate significant incidental findings to the referring physician for appropriate follow-up, especially if they represent a potential health risk. Failure to do so can lead to claims if a serious condition is missed.

- **4. High-Risk Lesions on Biopsy**

Certain benign-appearing lesions on imaging may turn out to be "high-risk" on biopsy (e.g., atypical ductal hyperplasia (ADH), lobular carcinoma in situ (LCIS), radial scar). These often warrant surgical excision due to an upgrade rate to malignancy. Failure to recommend or perform surgical excision for such lesions or inadequate communication of their significance, can lead to medico-legal issues if an associated cancer is later discovered.

5. Complications of Interventions

While complications like hematoma or infection are known risks of biopsies, severe or negligently managed complications can lead to claims. Examples include:

- **Nerve damage**: Though rare, can occur during biopsy or localization.
- **Pneumothorax**: A rare but serious complication of deep biopsies, especially those near the chest wall.
- **Infection**: If not adequately prevented or treated.
- **Failure to retrieve adequate tissue**: Leading to non-diagnostic biopsy and delayed diagnosis.

Risk Management and Prevention Strategies

Proactive risk management is essential for healthcare professionals in breast imaging and intervention. Key strategies include:

1. **Adherence to Guidelines**: Strictly follow national and international guidelines for breast imaging and intervention.
2. **Continuous Professional Development**: Regularly update knowledge and skills through conferences, workshops and peer-reviewed literature.
3. **Quality Assurance and Peer Review**: Participate in regular audits of diagnostic accuracy, discrepancy meetings and peer review of cases. This fosters a culture of learning and improvement.
4. **Robust Communication Protocols**: Establish clear protocols for communicating critical results and recommendations to referring physicians and patients.
5. **Comprehensive Documentation**: Maintain detailed, accurate and timely records of all aspects of patient care.
6. **Effective Patient Communication**: Ensure patients are fully informed and understand the risks, benefits and alternatives of procedures. Address patient concerns and questions patiently.
7. **Team Approach**: Foster a collaborative, multidisciplinary team environment where open communication and shared decision-making are encouraged

- 8.**Error Disclosure**: If an error occurs, transparent and empathetic disclosure to the patient and their family, along with an apology and a plan for remediation, can sometimes mitigate legal action and is ethically imperative.

9. **Professional Liability Insurance**: Maintain adequate professional liability insurance coverage.

10. **Manage Patient Expectations**: While not always easy, setting realistic expectations about the limitations of imaging, the possibility of false positives/negatives and the need for follow-up can reduce patient dissatisfaction and potential claims.

Conclusion

The medico-legal landscape of breast imaging and intervention is intricate and demanding. Healthcare professionals in this field bear significant responsibility for accurate diagnosis, timely management and compassionate care. Understanding the principles of duty of care, the critical importance of informed consent, the common pitfalls of diagnostic errors and the indispensable role of clear communication and meticulous documentation are not just legal necessities but fundamental components of ethical and high-quality medical practice. By adhering to established standards, engaging in continuous professional development, implementing robust quality assurance measures and prioritizing patient-centred communication, healthcare providers can significantly mitigate medico-legal risks. Ultimately, the goal is to provide the best possible care for patients with breast concerns, ensuring their safety and well-being while navigating the complexities of the legal environment. A proactive, diligent and patient-focused approach remains the most effective defence against potential litigation and the cornerstone of maintaining public trust in the vital field of breast healthcare.

References

- **FOGSI Medicolegal Handbook**. Federation of Obstetric and Gynaecological Societies of India (2021).
- **MCI Code of Ethics Regulations (2021)**. Medical Council of India.
- Vincent C., Burnett S. & Carthey J. T**he measurement and monitoring of safety.** J R Soc Med, 2020; 113(3): 101–104.
- American College of Radiology. **BI-RADS Atlas: Breast Imaging Reporting and Data System.** 5th Edition.
- Indian Radiological and Imaging Association (IRIA). **Guidelines on Breast Imaging and Interventions (2021)**.
- Dyer, C. **Breast cancer claims rise as imaging errors grow.** BMJ. 2019;364: k5304.